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CHRONIC KIDNEY DISEASE: VITAMIN D TREATMENT REGIMENS AND 
NOVEL ASSAY DEVELOPMENT FOR KIDNEY AND CARDIOVASCULAR 
FUNCTION BIOMARKERS 
 
JOE M. EL-KHOURY 
 
ABSTRACT 
 
Chronic kidney disease (CKD) is highly prevalent in the US population and has high 
incidence of cardiovascular and all-cause mortality. A known complication of CKD is 
secondary hyperparathyroidism that is caused by bone and mineral imbalances, including 
vitamin D deficiency. Supplementation of CKD patients with vitamin D is based on 
guidelines issued by the Kidney Disease Quality Outcomes Initiative (K/DOQI), which 
recommend administration of vitamin D2 in variable doses depending on the severity of 
vitamin D deficiency. Retrospective and pilot studies have shown that vitamin D2 was not 
as effective as vitamin D3 in treating vitamin D deficiency. In Chapter I, we investigated 
the effectiveness of vitamin D2 versus vitamin D3 treatment in resolving vitamin D 
deficiency in the pre-dialysis CKD population. This study was a double blinded, 
randomized, single center study that involved 22 CKD subjects. Data showed that 
vitamin D3 elicited a more rapid increase in 25-hydroxyvitamin D (25OHD) levels than 
vitamin D2, but both forms became equivalent in terms of the number of people who 
reached target 25OHD levels by the end of study. 
 viii 
Glomerular filtration rate (GFR) is the best overall index of kidney function. GFR is 
determined by measuring the urinary clearance of a radioactive exogenous biomarker, 
such as iothalamate, or estimated (eGFR) by measuring creatinine and adjusting for race, 
gender and age using equations. There are several known limitations to using creatinine-
based equations and radioactive substances exposure for eGFR and GFR determinations. 
In the remaining Chapters, solutions are proposed for measurement of GFR and eGFR, 
which involve liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chapter 
II discusses this technique and the process of development and validation of bioanlaytical 
methods by LC-MS/MS. Chapter III introduces a LC-MS/MS method for the 
measurement of L-arginine, symmetric dimethylarginine (SDMA), and asymmetric 
dimethylarginine (ADMA). SDMA was correlated with biomarkers of kidney function, 
while ADMA was correlated with biomarkers of cardiovascular disease. Chapter IV 
introduces a new LC-MS/MS method for the measurement of non-radioactive 
iothalamate to replace existing radioactive measurements for GFR determination. This 
method is very simple, fast, sensitive and selective and has shown good correlation with 
radioactive measurement of GFR. 
 ix
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CHAPTER I  
 
 
UPGRADE: A RANDOMIZED, DOUBLE BLIND STUDY TO EVALUATE THE 
EFFECTIVENESS OF CHOLECALCIFEROL VERSUS ERGOCALCIFEROL 
FOLLOWING KIDNEY DISEASE OUTCOMES QUALITY INITIATIVE 
(K/DOQI) GUIDELINES FOR VITAMIN D THERAPY IN STAGES 3 AND 4 
CHRONIC KIDNEY DISEASE (CKD) PATIENTS 
 
I.1.  Background and Rational 
According to the National Health and Nutrition Examination Surveys (NHANES) data 
set 1999-2004, 13.1% of the US population has chronic kidney disease (CKD), with 
80,000 newly diagnosed cases each year [1,2]. Hypovitaminosis D is very common (> 
86%) in pre-dialysis CKD patients [3-5], constituting 16.2 million of the US population 
[1,2]. This vitamin D deficiency/insufficiency is treated according to the 2003 Kidney 
Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Bone 
Metabolism and Disease in Chronic Kidney Disease published by the National Kidney 
Foundation (NKF) [6]. These guidelines recommend administration of ergocalciferol 
 2 
50,000 IU at either monthly or weekly intervals for 24 months depending on severity of 
vitamin D deficiency (mild/severe) or insufficiency. After cessation of therapy, it is 
recommended that patients are supplemented using vitamin D-containing multivitamins 
with annual reassessment of their vitamin D status. However, this regimen is believed to 
be inadequate in treating almost half of vitamin D deficient/insufficient CKD patients 
[7,3]. As a result, many physicians no longer adhere to K/DOQI guidelines, with one 
study identifying over 36 discrete vitamin D prescribing regimens in a single medical 
center [8]. Hence, there is a clear need to evaluate current K/DOQI guidelines, and 
establish effective treatment strategies. 
 
This study aimed to evaluate the adequacy of the current K/DOQI guidelines in leading to 
replacement of 25-hydroxyvitamin D (25OHD) levels. In addition, this study aimed to 
compare ergocalciferol in a head-to-head fashion with cholecalciferol treatment to better 
understand which vitamin D analogue is more effective in treating hypovitaminosis D in 
CKD patients. Because the K/DOQI guidelines are being reviewed and adopted by the 
international scene through Kidney Disease: Improving Global Outcomes (KDIGO), we 
expect that our findings will be relevant to the mission of NKF and will guide 
nephrologists worldwide in designing treatments for CKD patients, stages three and four, 
with vitamin D deficiency/insufficiency. In this study we have explored how 25OHD 
levels vary with ergocalciferol or cholecalciferol treatment per K/DOQI dosage 
guidelines and that what we have learned about these treatments will contribute to the 
formation of new K/DOQI and KDIGO clinical practice guidelines, impacting millions of 
CKD patients worldwide. Our focus was on the ability of each analogue to normalize 
 3 
25OHD levels (>31 ng/mL) for treated CKD patients. We also present literature data 
suggesting that ergocalciferol is less effective when compared to equimolar 
cholecalciferol in raising vitamin D to sufficiency levels or suppressing PTH levels in 
CKD patients, stages three and four. Therefore, our theory was that this proposal will 
likely lead to acknowledging that treatment following the K/DOQI Clinical Practice 
Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease is not highly 
effective, and new guidelines should be formulated that incorporate cholecalciferol 
instead of ergocalciferol for treatment of 25OHD deficiency/insufficiency. These 
outcomes have already been demonstrated for the vitamin D deficient Cystic Fibrosis 
population in separate studies, while here we attempted to resolve them in the same 
fashion but in a single study for the pre-dialysis CKD population. 
I.1.1.  K/DOQI definition and classification of CKD 
Current definition and classification of CKD patients are based on NKF KDOQI 
guidelines published in 2002 [9]. The K/DOQI working group defined chronic kidney 
disease as either a glomerular filtration rate (GFR) less than 60 mL/min per 1.73 m2 or 
the presence of kidney damage for a period of three months or more [9,10]. In addition, 
CKD patients are classified according to their GFR into five different stages: Stage 1- 
GFR greater than 90 mL/min/1.73 m2 with other evidence of kidney damage, Stage 2- 
GFR 60-89 mL/min/1.72m2 with other evidence of kidney damage, Stage 3 – GFR 30-59 
mL/min/1.73m2, Stage 4 – 15-29 mL/min/1.73m2 and Stage 5 - GFR of less than 15 
mL/min per 1.73 m2 or renal replacement therapy. GFR can be accurately measured or 
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estimated (eGFR) using creatinine-based equations. In this study, eGFR is calculated 
using the Modification of Diet in Renal Disease (MDRD) equation [11]. 
I.1.2. Vitamin D physiology, deficiency, and complications in general and CKD 
populations 
Unhydroxylated (inactive) vitamin D exists in two forms that simply differ by their side 
chain: ergocalciferol, also known as vitamin D2, or cholecalciferol, also known as 
vitamin D3 (Figure I.1). Cholecalciferol is synthesized from 7-dehydrocholesterol present 
in human skin upon exposure to UVB radiation [12], while ergocalciferol is synthesized 
from ergosterol in yeast and plants and is obtained by humans through their diet [13]. 
Upon entering the circulation, vitamin D (D2 or D3) binds to the vitamin D binding 
protein (DBP), where it is transported to the liver and hydroxylated by the enzyme 
Vitamin D 25-hydroxylase to 25OHD (calcidiol). This is the most abundant form of 
vitamin D in serum, with a half life of 2-3 weeks; it is used as a measure of the adequacy 
of a patient’s vitamin D stores [14]. However, vitamin D does not exert its pleiotropic 
effects until 25OHD is hydroxylated once more by 25-hydroxyvitamin D-1α-
hydroxylase, mainly in the kidneys, to 1,25-dihydroxyvitamin D (1,25[OH]2D, calcitriol). 
This active metabolite has a very short half life of 4-6 hours. It can enter the cell, bind to 
the vitamin D receptor (VDR) and subsequently lead to gene expression [15].  
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Figure I.1: Synthesis, activation and excretion of vitamin D. Reproduced from El-Khoury 
et al. [16]. 
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Unlike CKD, the exact definition and classification of vitamin D deficiency remains 
controversial. The 2011 public health report on dietary intake requirements for calcium 
and vitamin D from the Institute of Medicine [17] (IOM) recommend 20 ng/mL as the 
target 25OHD concentration for the general population, while the Clinical Practice 
Guidelines for the Evaluation, Treatment, and Prevention of Vitamin D Deficiency 
published by the Endocrine Society recommend 30 ng/mL [18]. As summarized by 
Rosen et al. [19], there are several reasons for this discrepancy, mainly that 25OHD > 30 
ng/mL does not confer any additional health benefits over 20 ng/mL.. Therefore, for the 
purpose of this study the targets we use are outlined in Table I.1 and defined for CKD 
patients by K/DOQI in their 2003 clinical practice guidelines for bone metabolism and 
disease in CKD [6]. Based on these recommendations, CKD patients presenting with a 
25OHD value of 15 ng/mL or below are considered vitamin D deficient, while patients 
with values ranging between 16 ng/mL and 30 ng/mL are considered vitamin D 
insufficient.  
 
Levels of 25OHD below 30 ng/mL have been associated with increased risk of falls [20], 
osteoporotic fractures [21-23], cancer [24-27], diabetes [28], hypertension [29], auto-
immune diseases [30-32], congestive heart failure [33], and all-cause and cardiovascular 
mortality [34].  
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Table I.1: K/DOQI Recommended Supplementation for Vitamin D 
Deficiency/Insufficiency in Patients with CKD Stages 3 and 4. 
 
Serum 25OHD, 
ng/mL (nmol/L) 
Ergocalciferol Dose 
(Vitamin D2) 
Duration 
(months) 
<5 (13) 50,000 IU/week orally ×12 weeks then 
monthly OR 500,000 IU as single 
intramuscular dose 
6 months 
5-15 (13-38) 50,000 IU/week orally × 4 weeks then 
monthly 
6 months 
16-30 (40-75) 50,000 IU/month orally 6 months 
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It was widely believed that the kidneys were the only sites of 1α-hydroxylation of 
calcidiol, which is why in the presence of CKD cholecalciferol and ergocalciferol 
supplementation received little attention [35]. Recent clinical studies have shown that 86-
89% of CKD patients are vitamin D deficient [3,4], and that low levels of 25OHD were 
associated with low levels of 1,25(OH)2D in CKD patients, independent of CKD 
progression [4,36]. These findings are explained by the fact that a wide variety of tissues 
in the human body, including immune cells, express VDR and/or 1α-hydroxylase and 
therefore respond to 1,25(OH)2D and/or can synthesize it locally from 25OHD, 
independent of renal conversion [37]. The high prevalence of hypovitaminosis D within 
the CKD population was explained by lack of sun exposure, malabsorption, inadequate 
intake, proteinuria [38], decreased synthesis of vitamin D3 in the skin due to impaired 
response to sunlight [39], advanced age [40], increased skin melanin levels [41], and 
progressive loss of 1α-hydroxylase enzyme effectiveness in converting 25OHD to 
1,25(OH)2D with progression of CKD [39]. The resulting deficiency in vitamin D, along 
with progressive loss of GFR in CKD patients, leads to stimulation of parathyroid 
hormone, a disorder known as secondary hyperparathyroidism (SHPT) [42]. SHPT is a 
common complication in CKD defined by elevated parathyroid hormone (PTH) levels, 
and is associated with mineral and bone disorders (MBD) such as renal osteodystrophy, 
which can lead directly to increased risk of bone fractures as well as an association with 
increased mortality [43,42]. Hence management of vitamin D deficiency, SHPT, and 
mineral homeostasis (calcium, phosphorus, and calcium-phosphorus product) is critical 
for CKD patients to reduce all-cause and cardiovascular mortality. 
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I.1.3. K/DOQI guidelines for vitamin D deficiency and SHPT 
As shown in Table I.1, guidelines from K/DOQI for treatment of vitamin D deficiency 
and SHPT in patients with stages 3 and 4 CKD recommend administration of 50,000 IU 
of vitamin D as ergocalciferol weekly for 4 or 12 weeks depending on vitamin D 
deficiency, and 50,000 IU monthly thereafter for a total duration of 6 months [Guideline 
8.2][6]. However, at the time of inception of these guidelines cholecalciferol was not 
available in such large doses, and ergocalciferol was thought to be the safer vitamin D 
sterol [44]. As a result, the released K/DOQI guidelines advocated the use of 
ergocalciferol over cholecalciferol, yet without controlled comparisons in humans to 
support that decision. Today, cholecalciferol supplements are available in doses as high 
as 100,000 IU, and such megadoses have been safely and efficaciously administered 
orally to CKD patients [45-47]. In one study up to 10,000 IU/day for 5 months of 
cholecalciferol did not cause toxicity and has been recommended as the safe upper limit 
in healthy adults [48]. Moreover, recent clinical studies evaluating modified versions of 
K/DOQI, have shown that ergocalciferol is only modestly effective in treating vitamin D 
deficiency and SHPT [7,3]. However, to date, no study has compared the efficacy of 
ergocalciferol to cholecalciferol in a head-to-head manner when following the K/DOQI 
guidelines. Nevertheless, limited data exist suggesting cholecalciferol is more efficacious 
at replacing vitamin D levels and there is no evidence to preferentially support 
ergocalciferol. It is very possible that the recommendation to use ergocalciferol is 
resulting in under replacement of vitamin D stores and contributing to the inadequacy of 
the K/DOQI dosing guidelines in replacing vitamin D. In addition, K/DOQI guidelines 
recommend continued supplementation with a vitamin-D-containing multi-vitamin 
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preparation for patients replete with vitamin D by the end of the treatment [Guideline 
8.3e][6]. Today, multivitamins contain only 400 IU of vitamin D (D2 or D3) [13], while 
studies have shown that more than 1000 IU/day of vitamin D is needed to maintain serum 
levels of 25OHD greater than 30 ng/mL [49,50]. Hence, patients currently taking 
multivitamin preparations as K/DOQI requires might not maintain their 25OHD levels in 
the required range. This is often seen clinically as vitamin D levels are frequently 
observed to drop after switching from high-dose to the low-dose vitamin D 
supplementation. As a result, there is a need to evaluate the efficacy of this dose at the 
end of the treatment to adequately maintain 25OHD within sufficiency levels. 
I.1.4. Ergocalciferol in pre-dialysis CKD patients: clinical trials 
Clinical studies on the efficiency of ergocalciferol in raising 25OHD and suppressing 
PTH in the CKD population have shown consistent results. In a prospective, 
nonrandomized, observational analysis using 52 stage 3 and 4 CKD patients with vitamin 
D deficiency/insufficiency and SHPT treated per a modified version of the K/DOQI 
guidelines using ergocalciferol, Zisman et al. [7] has shown that 60% reached 
recommended 25OHD levels by the end of treatment. In addition, 54% (stage 3) and 20% 
(stage 4) reached target 1,25(OH)2D levels, with 13.1% and 2.0% decreases in PTH, 
respectively. The authors concluded that with progression of CKD, there is decreased 
potential of improving PTH levels in spite of correcting calcidiol levels, probably due to 
decreased renal mass and ultimately decreased calcitriol production. It should be noted 
that ergocalciferol dosing was not as intense as recommended by K/DOQI, with the 
maximum duration of weekly interval being 4 weeks, regardless of 25OHD level. Other 
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studies yielded similar findings, for instance Deville et al. [51] using 85 stage 3-5 
(excluding those on dialysis) CKD patients has shown that despite an overall decrease in 
iPTH using ergocalciferol for 90 days in doses ranging from 800 IU/day to 100,000 
IU/week, only small numbers achieved K/DOQI target PTH levels. Also, Al-Aly et al. 
[3] retrospectively studied 66 stage three and four CKD male patients who were 
administered 50,000 IU/week ergocalciferol for 12 weeks and then 50,000 IU/month for a 
total of 6 months. The authors observed that almost half of patients (~45%) had a trivial 
or no increment in 25OHD at 6 months, and PTH levels decreased by 16.8% post-
treatment. It remains unclear how effectively 25OHD and PTH levels respond at the 
different dosing intervals and whether control was achieved at the more frequent interval 
then lost again by the end of the study after the monthly dosing interval period. This is 
suspected clinically by the authors as it often takes more than 12 weeks of weekly, high-
dose ergocalciferol therapy to fully replace 25OHD levels and the levels will frequently 
fall again within 4-8 weeks after once-monthly dosing is instituted. In conclusion, 
intermittent or high doses of ergocalciferol as recommended by K/DOQI may not be 
effective in raising 25OHD levels or suppressing PTH, and alternative options should be 
investigated. It is unclear whether this is due to inadequacy of the ergocalciferol 
formulation, the dosing pattern as recommended by K/DOQI or both. 
I.1.5. Cholecalciferol in pre-dialysis CKD patients: clinical trials 
Clinical studies investigating the efficiency of cholecalciferol in raising 25OHD and 
suppressing PTH in the CKD population suggest it may be more efficacious than 
ergocalciferol. In a randomized study including 87 stage 2-4 CKD patients with vitamin 
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D deficiency/insufficiency, Oksa et al. [52] has shown that treatment with either 5,000 
IU/week or 20,000 IU/week of cholecalciferol for 12 months corrects vitamin D 
deficiency/insufficiency, with the higher dose being more efficacious (39% versus 75% 
correction, respectively). In a small pilot study using 20 patients, Chandra et al. [53] has 
shown that treatment with 50,000 IU/week of cholecalciferol for three months results in 
90% of stage 3-4 CKD patients becoming vitamin D sufficient at the end of treatment, 
with 31% decrease in serum PTH levels. In comparison with results from Zisman et al. 
[7], cholecalciferol seems superior in raising 25OHD levels and PTH suppression, though 
a higher cumulative dose of vitamin D was used in Chandra’s study. In addition, in the 
DECALYOS II study (62), Kooienga studied 610 CKD patients with vitamin D 
deficiency who were treated with over the counter vitamin D (800 IU cholecalciferol) and 
calcium supplementation. PTH levels in patients with early stage 3 CKD (eGFR > 45 
mL/min/1.73m2) were controlled to goal in 90% after 6 months of treatment. PTH levels 
in patients with eGFR < 45 mL/min/1.73m2 were controlled to goal in 75% of patients. 
This is in the setting of adequate vitamin D replacement in only 41-49% of patients. 
Though the data supporting cholecalciferol is impressive, it is not adequate to definitively 
determine that it is a superior formulation to ergocalciferol for the replacement of 
25OHD levels and suppression of hyperparathyroidism in CKD patients. 
I.1.6. Treatment of hypovitaminosis D in Cystic Fibrosis (CF) patients: An example to 
follow 
In a manner similar to K/DOQI, the U.S. Cystic Fibrosis Foundation (CFF) gathered a 
panel of experts to develop treatment guidelines for hypovitaminosis D, which were 
published in 2005 [54]. Their treatment consisted of two regimen courses: 8 weeks of 
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treatment with ergocalciferol 50,000 IU/week, and if serum 25OHD levels fail to rise to 
30 ng/mL, it is followed by an additional treatment of 100,000 IU/week for 8 weeks. 
Shortly thereafter, a prospective clinical trial involving 66 adult CF patients evaluating 
the CFF published guidelines concluded that only 8% of patients had corrected 25OHD 
levels after treatment [55]. In addition, the same conclusions were reached in a 
retrospective clinical study involving pediatric CF patients, when only 43% reached 
serum 25OHD target levels using 150,000 IU/week ergocalciferol [56]. The inadequacy 
of ergocalciferol in treating vitamin D deficient/insufficient CF patients led to the 
investigation of cholecalciferol as a possible replacement. In a recent prospective clinical 
study comparing efficacy of treatment using ergocalciferol versus cholecalciferol in CF 
patients, 60% versus 100% of patients respectively became vitamin D sufficient after 
treatment with 50,000 IU/week for 12 weeks [57]. The outcome of the study was that 
cholecalciferol treatment is the more efficacious regimen for achieving optimal vitamin D 
status.  
I.2. Study Design and Procedures 
This study was approved by the Cleveland Clinic Institutional Review Board and was 
conducted at Cleveland Clinic facilities. 
I.2.1. Protocol Synopsis 
Title: UPGRADE: A Randomized Study to Evaluate the Effectiveness of Cholecalciferol 
versus Ergocalciferol following Kidney Disease Outcomes Quality Initiative (K/DOQI) 
Guidelines for Vitamin D Therapy in Stages 3 and 4 Chronic Kidney Disease (CKD) 
Patients 
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Indication: Vitamin D deficiency/insufficiency in subjects with stage 3 and 4 CKD not 
on dialysis. 
Primary Objective: 
To evaluate: 
Percent of subjects achieving 25-hydroxyvitamin D (25OHD) levels > 31 ng/mL 
(indicates vitamin D sufficiency) in chronic kidney disease subjects with vitamin D 
deficiency receiving high dose cholecalciferol versus subjects receiving high dose 
ergocalciferol per K/DOQI dosage and frequency guidelines.   
Secondary Objective(s): 
To evaluate: 
• Changes in absolute serum 25OHD levels over the course of the treatment 
• Absolute and percent changes in intact parathyroid hormone (iPTH), calcium 
(Ca), and phosphorous (P) 
• For subjects with corrected 25OHD, the efficacy of daily vitamin D containing 
multi-vitamin supplementation in maintaining serum 25OHD levels at goal after 
cessation of high-dose therapy. 
• Safety and tolerability of cholecalciferol and ergocalciferol. 
• Incidence of symptomatic adverse effects. 
• Incidence of hypercalcemia or hyperphosphatemia. 
Hypothesis: 
The clinical hypothesis of this study is that a treatment regimen including high dose 
cholecalciferol will raise 25OHD levels to normal for a greater percentage of treated 
patients over the six months K/DOQI recommended treatment period compared with a 
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treatment regimen that includes high dose ergocalciferol, in subjects with stage 3 or 4 
CKD with vitamin D deficiency/insufficiency. 
 
Study Design:  
This single-center, randomized, double-blind, open-label trial will consist of 3 phases: 
1.  Patient screening to assess for eligibility for the study. Labs will be 
considered valid for use to meet inclusion and exclusion criteria if the 
were completed within 45 days of screening.  
Eligible subjects will be randomized to either: 
• Group A- Vitamin D2 group: high dose of ergocalciferol 
• Group B- Vitamin D3 group: high dose of cholecalciferol 
2.  A treatment phase lasting 24 weeks 
3.  A follow-up phase lasting 12 weeks 
Primary and Secondary Endpoints: 
Primary 
Percent of subjects with vitamin D sufficiency (25OHD > 31 ng/mL) at weeks 12 and 24 
Secondary 
Absolute change of 25OHD levels from baseline to end of study (week 24) 
Absolute in iPTH from baseline to end of study (week 24) 
Absolute change from baseline to end of study (weeks 6 through 36) in calcium and 
phosphorus. 
The safety of cholecalciferol and ergocalciferol as determined by the nature, frequency, 
severity, and relationship to treatment of adverse events 
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Sample Size: 
A total of 22 subjects were randomized into this study at a 1:1 ratio: 
• Control group (11 subjects) 
• Cholecalciferol group (11 subjects) 
Randomization was stratified by severity of 25OHD deficiency (insufficient: ≤ 30 to 16 
ng/mL, mild deficiency: ≤ 15 to 5 ng/mL, and severe deficiency: < 5 ng/mL) 
Summary of Subject Eligibility Criteria 
Inclusion criteria: 
• Adults ≥ 18 years 
• Chronic kidney disease stage 3-4 (eGFR 15-59 mL/min/1.73m2 body surface area, 
calculated using the MDRD Study equation GFR calculator) 
• Hypovitaminosis D (serum 25OHD < 31 ng/mL) 
Exclusion criteria: 
• History of liver failure  
• History of intestinal malabsorption or chronic diarrhea 
• Serum calcium level greater than 10.2 mg/dL 
• Treatment with an activated vitamin D formulation (calcitriol, doxercalciferol or 
paracalcitol) within the past 6 months 
• Treatment with phenobarbital, phenytoin, rifampicin, sucralfate, steroids, digoxin, 
or other medications that could affect vitamin D metabolism 
• Primary hyperparathyroidism, active of a prior history of such 
• Active malignancy excluding basal cell or localized squamous cell skin cancer 
• Subject is pregnant (e.g. positive HCG test) or breast-feeding 
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• Refusal to use highly effective contraceptive measures (as determined by the 
investigator) throughout the treatment phase of the study 
• Serum phosphorus level greater than 4.5 or treatment with an oral phosphate 
binder within the past 6 months  
• Treatment with cinacalcet or other calcimimetic within the past 6 months 
• Anticipated dialysis within 6 months after randomization 
• Inability to swallow tablets 
• Known sensitivity, intolerance, or other adverse response to the study drugs 
which would prevent compliance with study medication 
• Have an unstable medical condition, defined as having been hospitalized within 
30 days before screening, the expectation of recurrent hospital admissions or life 
expectancy of less than 6 months in the judgment of the investigator 
• Subject is currently enrolled in, or fewer than 30 days have passed since subject 
has completed another investigational device or drug study(s); or subject is 
receiving another investigational agent(s). 
Treatment Group: 
The treatment group received cholecalciferol provided in tablets of 1.25 mg, the 
equivalent of 50,000 IU, and dosing per K/DOQI guidelines. 
Control Group: 
The control group received ergocalciferol also provided in tablets of 1.25 mg and dosing 
per K/DOQI guidelines. Pills are green and oval shaped, imprinted with a circled W on 
one side and “D 92”on the other. 
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Procedures: 
 
General 
Enrolled subjects were assigned to one of two arms of therapy to replace vitamin D. 
Monitoring was performed via phone interviews only, to include medication tracking, 
reminders to have labs drawn and to screen for adverse events. 
Clinical appointments were made at the discretion of the responsible clinical 
Nephrologist outside of the study. 
All laboratory specimens were drawn either at CCF Main hospital labs or at a CCF 
family Health center lab to ensure specimens are processed at the CCF Main core 
laboratory. 
 
Patient Screening 
Patients were identified as potential candidates for enrollment by the Nephrology 
provider caring for them. Once identified, a study investigator made sure the patient 
meets enrollment criteria of having stage 3 or 4 CKD and low vitamin D levels.  
In order to ensure eligibility for the study, laboratory tests were performed within 45 days 
of enrollment. These tests included results of 25OHD, iPTH and serum creatinine level 
for GFR assessment. Subjects meeting eligibility criteria were approached for consent 
and enrollment in the study. Once consented, if not already completed in the past 45 days, 
1,25(OH)2D, calcium, phosphorus, albumin levels and serum pregnancy test (for all 
women of child-bearing potential) were ordered. A brief clinical history was collected 
from the medical chart and from the patient interview. Patients were randomized to a 
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treatment arm. Women of child-bearing age were instructed not to start the study 
medication until the pregnancy test is confirmed to be negative. 
Randomization was stratified by severity of 25OHD deficiency (insufficient: ≤ 30 to 16 
ng/mL, mild deficiency: ≤ 15 to 5 ng/mL, and severe deficiency: < 5 ng/mL). 
All other vitamin D supplements were stopped at the time of enrollment.  
 
Study Start Date 
The study start date of this study is defined as the day when the study medication is 
started. 
 
Treatment Phase 
The treatment phase was 24 weeks (6 months) in duration. Blood was collected in the 
laboratory every 6 weeks starting at day 1. 1,25(OH)2D, 25OHD, iPTH, and renal 
function panel were obtained at the week 6, 12, 18, and 24 study visits. 
Subjects randomized to the cholecalciferol (D3) treatment group received 1.25mg 
(50,000 IU) cholecalciferol at an interval dependent on the severity of their vitamin D 
deficiency/insufficiency similar to K/DOQI guidelines recommendation for treatment of 
hypovitaminosis D. Subjects with severe vitamin D deficiency (25OHD < 5 ng/mL) 
received a single dose once weekly for 12 weeks followed by a single dose once monthly 
for 3 months. Subjects with mild vitamin D deficiency (25OHD: 5 to 15 ng/mL) received 
a single dose once weekly for 4 weeks followed by a single dose once monthly for 5 
months. Subjects with vitamin D insufficiency (25OHD: 16 to 30 ng/mL) received a 
single dose once monthly for six months. In the event of hypercalcemia or 
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hyperphosphatemia, changes in vitamin D and/or calcium containing phosphate binder 
dose were considered in accordance with treatment practice guidelines. 
Subjects randomized to the ergocalciferol (D2) group received ergocalciferol following 
the K/DOQI guidelines recommendation for treatment of hypovitaminosis D, which 
follows the same dosage pattern as the cholecalciferol treatment group, except 
ergocalciferol 1.25 mg (50,000IU) is used.  
 
In the event of hypercalcemia or hyperphosphatemia, communication was made with the 
subject’s responsible Nephrologist and any calcium supplements were stopped. If 
hypercalcemia persists, then the interval of vitamin D administration was decreased in 
accordance with treatment practice guidelines. Vitamin D was stopped and the patient 
censored if hypercalcemia persisted despite medication adjustments. 
 
Follow-up Phase 
The follow-up phase lasted 12 weeks, with lab visits every 6 weeks to measure 
1,25(OH)2D, 25OHD, iPTH, and renal function panel. Subjects in both treatment groups 
with 25OHD serum levels > 31 ng/mL received vitamin D containing multi-vitamin 
preparations at a vitamin D dose of 10 µg/day (400 IU) for 12 weeks. All other subjects 
were censored from the study at this stage, and continued to receive recommended 
treatment for their persistent vitamin D deficiency and/or hyperparathyroidism through 
their responsible Nephrologist. 
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Statistical Considerations 
The study was originally planned to have 86 subjects randomized to each of the control 
and treatment groups, which would have given enough power to detect differences in 
PTH suppression between the two treatments. However, due to the slower than expected 
enrollment rate, the power calculations were re-examined and the study was adjusted to 
only detect differences in 25OHD reaching target level (primary outcome). This study 
was geared to have 80% power to detect differences of 90% in cholecalciferol group 
versus 60% in control group in percent of subjects vitamin D sufficient (25OHD > 31 
ng/mL) after 12 and 24 weeks of treatment, with alpha level of 0.05 (two-sided). The 
power analysis resulted in a calculated sample size of 11 per treatment group, and 22 
total. 
Other laboratory variables will be summarized.  
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Figure I.2: Schematic illustration of UPGRADE study design. 
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Figure I.3: Schematic illustration showing the vitamin D treatment regimen used in 
UPGRADE. 
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1.25 mg/week 
1.25 mg/month 
10 mcg/day 
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Table I.2: Schedule of laboratory blood tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Treatment Phase Follow-up Phase Treatments and 
Procedures Screen Day 1 W6 W12 W18 W24 W30 W36 
Informed Consent (a) X               
Medical History X               
Serum pregnancy test (all 
women  
of child bearing potential) 
 X             
25OHD level X  X X X X X X (e) X (e) 
iPTH level X  X X X X X X (e) X (e) 
Calcitriol level   X X X X X X (e) X (e) 
Renal function panel X  X X X X X X (e) X (e) 
Additional serum samples 
(b)     X  X X X X X (e) X (e) 
Drug Dispensing  X (c)    X (d)   
a) To occur before any study 
procedure         
b) Collection of additional serum samples may not be applicable for all 
subjects 
c) Bottles containing 50,000 IU cholecalciferol or ergocalciferol will be 
dispensed to subjects randomized within each respective group 
d) Subjects with normal 25OHD and PTH at this stage will be dispensed 
multi-vitamin bottles 
e) Only subjects dispensed multi-vitamins will be followed-up 
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I.2.2. Blood Collection Protocol 
Label Preparation 
1. Each subject will have a three (3) digit number assigned to them (ex. 067) 
2. a. For samples to be stored in freezer: Add “UPG” before the 3 digit number 
followed by the tube id for each tube (ex. UPG055W18Gold3). W18 refers to 
week 18 sample and Gold to tube 
b. For samples to be taken to Central Processing Area: Label as Last Name: 
Upgrade, First Name: 3 digit numbers followed by week (ex: Upgrade, 055W18)  
 
Sample Aliquoting and Storing 
1. For each participant an UPGRADE Study Sample Checklist must be completed 
(See Section I.2.3). These are found in print form in the UPGRADE Study folder. 
Once completed these will be stored in the patient’s section in that same folder 
for database entry. 
2. Prepare labels for the days participants  
a. For week 1 patients, labels are printed on the spot using the Dymo 
LabelWriter 
b. Patients past week 1 have their labels printed out and ready in their 
designated section in the brown folder 
3. For weeks 1,18, 30, and 36: Gold (G) and (if research consented) Purple (P) tubes 
will be delivered directly to research area of special chemistry. If no one is 
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available at time of receipt, samples will be stored in CPA freezer and a 
voicemail will be recorded at 47003 to inform of receipt. 
For weeks 6, 12 and 24: G tubes must be located in freezer after receiving 
identifiable information provided by nurses. 
4. G and P tubes will be centrifuged at 2000 x g for 10 min. 
5. Remove the appropriate number of cryogenic vials depending on whether or not 
patient is research consented and week # (See checklist and form) 
6. Arrange tubes by color code in 12 x 6 small racks (Regular cryotube for aliquots 
from Gold tubes and purple coded cryotubes for aliquots from Purple tube). 
7. Uncap only one color at a time and aliquot appropriate amount into each tube 
listed in the checklist then recap tubes.  
a. For week 1 patients, if extra tests are needed, tubes W1Gold2 and 
W1Gold3 are aliquoted into 75 x 12 mm tubes (available at CPA) labeled 
appropriately (e.g.“Upgrade, 001W1Gold2”) and requested tests are 
checked in the list (Check email to see which tests should be ordered). 
These tubes are then taken to CPA along with a copy of the checklist, 
which serves as a requisition form. If no extra tests required, store 
aliquots in cryotubes and label as W1Gold2 and W1Gold3.  
b. For weeks 18,30 or 36, Gold1-3 are aliquoted in 75 x 12 mm tubes and 
labeled appropriately. These tubes are then taken to CPA along with a 
copy of the checklist, which serves as a requisition form. 
c. All other tubes are stored in cryogenic vials and placed in a labeled freezer 
box. 
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8. Each box should contain 5 NON research consented patients OR only 1 research 
consented patient. If box is being used for a research consented subject, then 
place tag on box (cover and inside) and also mark as “Research Consented”. 
9. Place samples in freezer #49012, currently used for Reference Range Study in the 
front area of L1-140. 
10. Samples go to the fourth shelf from the top, starting from first rack (left to right) 
in the first available space (front to back). 
11. Retrieve results from Sunquest using Last and First Name provided on tube 
12. Report results using coded reference number to the following email list: 
a. brienzr@ccf.org 
b. garciam1@ccf.org 
c. sweene1@ccf.org 
d. seifert@ccf.org 
e. simonj2@ccf.org 
 
13. Store original checklist along with instruction form in brown folder. Each patient 
is stored in 1 slot. 
I.2.3. Sample Checklists 
A total of 6 sample checklists are used in this study, which vary based on agreement of 
patient to additional research procedures and the number of weeks the patient has been in 
the study. These checklists are listed in the Appendix. 
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I.2.4.  25OHD, PTH, Calcium and Phosphorus Analysis 
Serum samples were analyzed for 25OHD using a chemiluminescence immunoassay 
(Liaison®, Diasorin, Stillwater, MN). According to the manufacturer’s insert 
(US310600; 37085) the assay is linear from 4.0 to 150 ng/mL with  %CV less than 12.6% 
across different concentrations, lots and sites (following CLSI EP5-A2 guidelines). Intact 
PTH was analyzed on the ADVIA Centaur Assay (Siemens, Tarrytown, NY). According 
to the manufacturer’s insert (129461 Rev E. 2004-05) the assay is linear from 2.5 to 1900 
pg/mL with a total %CV less than 7.8 at three different concentrations tested over a 4 day 
period (n=144 for each sample). Serum/plasma calcium and phosphorus were both 
analyzed on the Roche P Modular System (Indianapolis, IN). The method is linear from 
0.2 to 20.0 mg/dL and 0.3 to 20.0 mg/dL for calcium and phosphorus, respectively. 
I.3.  Results and Discussion 
I.3.1. Baseline Subject Characteristics 
Twenty-two subjects were eligible on prescreening on the basis of eGFR, 25OHD, PTH, 
calcium and phosphorus levels, and gave consent. Two subjects were withdrawn from the 
study before beginning with supplementation because their repeat 25OHD test on day 1 
returned as >31 ng/mL. Two subjects were withdrawn from the study because they were 
started on dialysis during treatment. Another subject was withdrawn from the study 
because subject did not take the dosage as prescribed. During the study, three subjects 
withdrew consent, two were lost during follow-up and the third dropped out right after 
baseline measurements were performed. Data for the two patients lost to follow-up are 
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also included in the analysis. Thus, a total of 16 subjects (8 in each treatment group) 
completed the treatment phase, of which 8 were eligible for the follow-up phase, but only 
6 completed it (3 from each treatment group). 
 
Subjects in the vitamin D2 and vitamin D3 treatment groups were similar with respect to 
age, ethnicity, sex, eGFR, 25OHD, PTH, calcium and phosphorus (Table I.3). 
I.3.2. Primary Endpoint: Percent of Subjects Achieving Goal 25OHD Level 
Changes in the primary endpoint are summarized in Table I.4. Differences in the number 
and percent of subjects achieving 25OHD levels > 31 ng/mL between the two treatment 
groups were significant at week 12 (0 for D2 versus 5 for D3). However, by the end of 
treatment (week 24), both treatment groups had the same number of patients achieve goal 
25OHD levels. This suggests both treatments are equally effective in raising 25OHD, but 
may exhibit different pharmacokinetics. However, it is important to note that given the 
small number of study subjects included, this study does not have significant power and 
therefore the findings are only preliminary and should serve as a basis for larger well 
controlled clinical trials. 
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Table I.3: Baseline characteristics of patients with chronic kidney disease treated with 
vitamin D2 or vitamin D3 
 
Characteristics Vitamin D2 Group Vitamin D3 Group 
Total, n 8 8 
Age, y 64.50 (7.29) 67.63 (12.63) 
Ethnicity, n:  
A. African American 
B. Nonhispanic White  
A. 4 
B. 4 
A. 4 
B. 4 
Female, n 2 4 
eGFR, mL/min/1.73 m2 39.4 (14.1) 36.9 (12.8) 
25OHD, ng/mL 17.1 (4.9) 20.3 (6.9) 
PTH, pg/mL 137 (62) 126 (42) 
Calcium, mg/dL 9.7 (0.6) 9.6 (0.3) 
Phosphorus, mg/dL 3.5 (0.7) 3.7 (0.5) 
Values in parenthesis represent standard deviations.  
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Table I.4: Absolute and percent of subjects achieving 25OHD levels > 31 ng/mL during 
the course of the treatment. 
 
No. (%) of subjects with 
25OHD > 31 ng/mL 
Baseline Week 6 Week 12 Week 18 Week 24 
Vitamin D2 Group, n=8 0 (0) 2 (25%) 0 (0%) 2 (25%) 4 (50%) 
Vitamin D3 Group, n=8 0 (0) 3 (38%) 5 (63%) 4 (50%) 4 (50%) 
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I.3.3. Secondary Endpoint: Serial 25OHD, PTH, Calcium and Phosphorus Levels 
Changes in the secondary endpoints are summarized in Table I.5. Differences in 25OHD 
between the two treatment groups were not significant at baseline (P=0.30), but began to 
emerge at week 6 (P=0.07), week 12 (P=0.07) and week 18 (P=0.02). However, these 
differences were completely resolved by week 24 (P=0.57), suggesting that by the end of 
treatment, both vitamin D forms were equivalent. When the baseline values were 
subtracted for each group, the increase in 25OHD after vitamin D2 or vitamin D3 
administration were not statistically different (P > 0.38 for all weeks measured). Both 
treatments showed elevations in 25OHD that were significantly different than baseline (P 
< 0.05) from week 6 and on. There was no significant difference in PTH, calcium or 
phosphorus between the two treatment groups over the duration of the treatment. In 
addition, 2 subjects in the D2 treated group versus 1 subject in the D3 treated group 
developed hyperphosphatemia (Phos > 4.5 mg/dL) during the course of the treatment, 
while no subject developed hypercalcemia (Ca > 10.5 mg/dL).  
 
Figure I.4 shows the 25OHD response profiles of the two treatment groups during the 24-
week study. Also, it was noted that two patients in each treatment group did not have a 
significant response to treatment (non-responders), defined by a change of 25OHD less 
than 5 ng/mL. Figure I.5 shows the same response profiles after eliminating the non-
responders from the analysis.  
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I.3.4. Follow-up Phase: Multivitamins for Maintaining 25OHD Levels 
By the end of week 24, 8 subjects out of 16 were eligible to participate in the follow-up 
phase, but only 6 (3 from each treatment group) completed this phase. Multivitamins 
containing 400 IU of vitamin D3 were prescribed daily for 12 weeks, with the subjects 
assessed every 6 weeks. Of the 6 patients on multivitamins, 5 (83%) successfully 
maintained 25OHD levels > 31 ng/mL after 12 weeks (data not shown). 
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Table I.5: Serial measurements of 25OHD, PTH, calcium and phosphorus in chronic 
kidney disease patients treated with either vitamin D2 or vitamin D3 
 
25OHD, ng/mL Baseline Week 6 Week 12 Week 18 Week 24 
Vitamin D2 
Group, n=8 
17.1 ± 4.9 25.0 ± 6.3 24.8 ± 6.8 25.2 ± 6.0 29.4 ± 9.5 
Vitamin D3 
Group, n=8 
20.3 ± 6.9 31.9 ± 7.7 31.3 ± 6.5 32.1 ± 4.8 32.1 ± 9.1 
P-value 0.30 0.07 0.07 0.02 0.57 
PTH, pg/mL      
Vitamin D2 
Group, n=8 
137 ± 62 171 ± 126 174 ± 114 167 ± 115 183 ± 148 
Vitamin D3 
Group, n=8 
126 ± 42 105 ± 57 105 ± 55 145 ± 94 96 ± 43 
P-value 0.71 0.20 0.16 0.67 0.15 
Calcium      
Vitamin D2 
Group, n=8 
9.7 ± 0.6 9.4 ± 0.6 9.3 ± 0.5 9.2 ± 0.6 9.3 ± 0.6 
Vitamin D3 
Group, n=8 
9.6 ± 0.3 9.4 ± 0.5 9.6 ± 0.2 9.1 ± 0.3 9.6 ± 0.4 
P-value 0.64 0.93 0.10 0.65 0.27 
Phosphorus      
Vitamin D2 
Group, n=8 
3.5 ± 0.7 3.8 ± 0.8 3.4 ± 0.7 3.8 ± 0.8 3.2 ± 0.5 
Vitamin D3 
Group, n=8 
3.7 ± 0.5 3.4 ± 0.6 3.5 ± 0.5 3.5 ± 0.9 3.6 ± 0.8 
P-value 0.64 0.25 0.67 0.56 0.28 
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Figure I.4: Comparison of vitamin D2 (n=8) versus vitamin D3 (n=8) treatment per 
K/DOQI guidelines in raising 25OHD levels. Standard deviation bars are displayed. 
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Figure I.5: Comparison of vitamin D2 (n=6) versus vitamin D3 (n=6) treatment per 
K/DOQI guidelines in raising 25OHD levels after eliminating non-responders to 
treatment (n=4), defined by ∆25OHD < 5 ng/mL. Standard deviation bars are displayed. 
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I.4.  Conclusion 
In conclusion, the findings from this pilot study show that both vitamin D2 and vitamin 
D3 are equally moderately effective (50%) when used per K/DOQI guidelines to treat 
vitamin D deficiency in stage 3 and 4 CKD patients. This implies that new treatment 
strategies should be designed to ensure that the maximum number of patients reach the 
25OHD target level of 31 ng/mL. However, the data also showed that both forms of 
vitamin D exhibit different pharmacokinetic profiles, with vitamin D3 causing a more 
rapid and sustained increase. In addition, daily mulitvitamins with 400 IU of vitamin D 
were found to be an effective strategy for maintaining 25OHD level > 31 ng/mL for the 
majority (83%) of CKD patients for at least 12 weeks. Aside from three cases of 
hyperphosphatemia, no signs of toxicity or side effects were observed from treatment 
with either form of vitamin D using K/DOQI guidelines.  
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CHAPTER II  
 
LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD 
DEVELOPMENT AND VALIDATION 
 
II.1. Introduction to Liquid Chromatography-Tandem Mass Spectrometry 
II.1.1. Liquid Chromatography-Tandem Mass Spectrometry in the Clinical Laboratory 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a highly specialized 
analytical technique that is gaining widespread use in the clinical laboratory [1]. When 
first introduced, it was primarily used for the analysis of challenging low molecular 
weight compounds, such as vitamin D metabolites [2] and steroids [3]. These analytes 
required higher sensitivity and specificity than afforded by immunoassays (Figure II.1). 
However, LC-MS/MS has now expanded to include the analysis of proteins [4] and 
metabolic profiling [5]. For the purpose of this dissertation, the focus will be on the use 
of LC-MS/MS for the analysis of small molecules. The strengths, weaknesses, 
opportunities and threats (SWOT) of this technology are summarized in Table II.1.  
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 There are several types of MS analyzers that can be coupled to LC systems and be 
used for the identification and quantification of small molecules, but triple quadrupole 
instruments represent the gold standard for LC-MS/MS analysis in clinical laboratories 
[6]. Although they have lower resolution when compared with other mass analyzers, 
triple quadrupole instruments provide a combination of superior sensitivity, selectivity 
and quantitative performance, making them ideal for quantitative analysis (Table II.2).
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Figure II.1: Dynamic range of low molecular weight biomarkers in adult human serum. 
Shown are mean and ranges. Reproduced from [1]. 
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Table II.1: Analysis of LC-MS strength, weakness, opportunities, and threats (SWOT) in 
clinical diagnostics. Adapted from [1]. 
Strengths 
High Sensitivity 
High Selectivity 
High speed of development at low costs of 
new assays when compared to 
immunoassays by IVD companies 
Low costs per sample in terms of reagents 
Possibility to measure multiple analytes in 
the same sample simultaneously 
Versatility 
Near reference methodology in routine 
setting 
Matrix independency (saliva, CSF, urine, 
etc.) 
Compatible with automated sample 
handling configurations 
Weaknesses 
High instrument costs 
Serial (batch-wise), non random-access 
operation 
Need for highly skilled personnel for 
method development, validation, operation 
and troubleshooting 
Lack of clearly defined quality regulations 
Limited sample throughput in conventional 
set–up 
Absence or limited availability of CE/IVD 
approved reagent-kits 
Limited experience of IVD requirements 
from MS vendors 
Opportunities 
Progress towards more user-friendly 
instruments (with integration of all 
components into a single system) 
Adoption of MS technology by major IVD 
companies 
Broader availability of CE/IVD approved 
kits for LC-MS/MS analysis 
Quantitative measurement of peptides and 
proteins 
Profiling of metabolically related 
metabolites (context) 
Threats 
Speed of development of new instruments 
> hard to keep up with 
Growing difficulty finding (skilled) 
technicians (and experience at an academic 
level) 
Lack of commitment from major IVD 
companies 
Regulatory bodies applying restrictions on 
using home-brew assays for diagnostic 
purposes 
Competition from innovations in 
immunoassays or from the introduction of 
new technologies 
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Table II.2: Comparison of the general features of single and triple quad instruments with 
quadrupole-time-of-flight (Q-TOF) and linear ion trap orbitrap (LTQ-orbitrap). 
Reproduced from [6]. 
 
 Single Quad Triple Quad Q-TOF LTQ-Orbitrap 
Sensitivity + +++ +++ +++ 
Selectivity + +++ +++ +++ 
Resolution + + +++ +++ 
Performance for 
quantification 
++ +++ ++ ++ 
Identification of 
target compounds 
++ +++ +++ +++ 
Identification of 
unknown 
compounds 
+ ++ +++ +++ 
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II.1.2. Liquid Chromatography-Triple Quadrupole Mass Spectrometry  
Liquid chromatography-triple quadrupole mass spectrometry involves various stages of 
purification and separation that render it the gold standard for the analysis of low 
molecular weight analytes. The process involved is outlined in Figure II.2 and begins 
with obtaining a blood, serum or plasma tube, which is usually centrifuged to separate 
cells from plasma/serum (except in the case of intracellular analytes). The resulting 
supernatant (plasma/serum) is further purified by various sample preparation techniques 
to reduce the complexity of the biological matrix before introduction to the LC system. 
Purification by LC relies on the partition of the analyte between a stationary phase of 
choice (analytical column) and a mobile phase. The selection of the stationary phase 
depends on the properties of the analyte itself and creates an interaction with the analyte 
that is based on adsorption chromatography, ion-exchange chromatography, size-
exclusion chromatography, or hydrophilic interaction chromatography (HILIC). The 
analytical column separates compounds into classes by having different affinities for 
them. The group of compounds that contains the analyte is then directed into the ion 
source of the mass spectrometer where gaseous ions are created by a combined process of 
evaporation and ionization. For most methods, this is achieved by either using 
atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). APCI 
evaporates the compounds first by applying really high temperatures, and then ionizes the 
gaseous compounds via a charged corona needle before introducing them to the MS. On 
the other hand, ESI ionizes the surface of the solvent droplets first prior to evaporation 
and introduction into the MS. The two sources have differing applications, with ESI 
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being preferred for thermally unstable, larger molecular weight or very polar compounds. 
After the formation of gas phase ions, the beam of ions entering the MS is directed to the 
first quadrupole (Q1), where mass selection of the charged precursor ion is performed. 
This beam of ions then enters the collision cell (Q2), where the precursor ion is collided 
with an inert gas to induce the formation of product ions. The beam of product ions is 
then directed to the third quadrupole (Q3), where the product ion selection occurs, which 
is then sent to the electron multiplier to be detected. The end result is a chromatogram 
displaying relative ion intensity to retention time off the column for a particular reaction 
sequence that is monitored. 
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Figure II.2: Illustration of the steps involved in LC-MS/MS analysis. (a) Blood tubes are 
first centrifuged with the resulting supernatant (plasma or serum) transferred to a 
centrifuge tube. Plasma or serum is then further purified by (b) protein precipitation, (c) 
liquid-liquid extraction, (d) solid-phase extraction, derivatization, or online sample clean-
up prior to injection onto the LC system. (e) Chromatographic separation is then 
performed on the analytical column before (f) evaporation and ionization of the analyte in 
the ion source and (g) being introduced through the ion tube into the MS. The (h) first 
quadrupole selects the precursor ion of the desired analyte, while the (i) second 
quadrupole fragments that ion by collision with an inert gas. The (j) third quadrupole then 
selects the product ion that is then (k) detected and quantified. 
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II.1.3. LC-MS/MS Method Development 
The various steps involved in LC-MS/MS method development include optimization of 
the MS conditions, the LC conditions, and sample preparation procedures. They are 
followed in that order exactly because the MS parameters can be optimized independent 
of the LC parameters, which can be optimized independent of sample preparation 
procedures, but the reverse is not true. Optimization of the MS and LC parameters can be 
performed using solvent based solutions, and optimizing the MS first allows the detection 
of the analyte. This is then followed by the LC optimization which allows us to observe 
how well the analytical column retains our analyte and chromatographically resolves any 
potential interference. Then sample preparation is optimized to purify analyte from any 
interferences that could not be resolved by the LC-MS/MS platform, and to provide a 
cleaner extract for injection. The final composition of the extract is optimized to match 
the initial mobile phase conditions used for the LC separation. 
II.1.3.1. Mass Spectrometry Optimization 
This is generally the first step in LC-MS/MS method development and it involves 
preparation of a solvent based solution containing the analyte at a relatively high 
concentration (typically 1 µg/mL). This solution is then infused to the MS using a syringe 
pump. The MS is typically set to scan mode at start so that the expected peak is first 
identified. After locating the expected peak corresponding to the molecular weight of the 
analyte, the ion source conditions are optimized. Ion source conditions depend on the 
choice of ion source, ESI or APCI. In ESI, the ion source parameters that can be 
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optimized are spray voltage, capillary temperature, ion sweep gas, sheath gas, and 
auxiliary gas. In APCI, the only difference is instead of spray voltage there is corona 
needle voltage. The correct combination of parameters allows maximum number of 
analyte molecules to evaporate and ionize from the LC through the ion transfer tube and 
on to the MS, while reducing background noise. 
 
After optimization of the ion source parameters, the MS mode is changed from scanning 
to product ion monitoring. In this mode, a selected mass/charge range is fragmented into 
several product ions using different collision energies. The purpose is to select a product 
ion in Q3 with the highest sensitivity to monitor for quantification, and possibly a second 
product ion for qualification.  
 
After completion of this step, the MS mode is changed from product ion monitoring to 
single (SRM) or multiple reaction monitoring (MRM), depending on the number of 
analytes we are measuring. In this mode, the information gathered from the previous 
experiments is input together (Q1 m/z, collision energy, Q3 m/z) and a MS method is 
created. 
II.1.3.2. Liquid Chromatography Optimization 
Upon optimization of the MS conditions using solvent based solutions and creation of an 
MS method, development begins on the LC portion of the assay. In this step, there are 
three basic elements that need to be selected before optimization begins: a) analytical 
column, b) Mobile phase A, and c) Mobile phase B. As a general rule of thumb, it is 
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simpler and faster to test different analytical columns than to test different mobile phases. 
So, generic mobile phases spiked with additives (ammonium acetate, formic acid, 
trifluoroacetic acid…) are used at start, such as water with formic acid for mobile phase 
A and methanol for mobile phase B, and a variety of columns are tested using a general 
gradient. Whichever column provides the best retention, recovery of the analyte and peak 
shape is the one selected for further optimization. Then the mobile phases, flow rates and 
gradients are optimized using the solvent based solution. It would be wise at this stage to 
also prepare solvent based solutions of any potential isobaric (same molecular weight) 
interferences that we would like to chromatographically separate and inject those as well 
to make sure the LC method separates interferences from our compound. 
II.1.3.3. Sample Preparation Optimization 
Once LC optimization has been completed, it is time to begin optimizing sample 
preparation procedures using actual patient matrix, such as serum or plasma. In this step, 
we should be aware of any potential interference that was not separated by MS or the LC 
method and attempt to separate it in this stage. Besides separating interferences, the 
objective of the sample preparation is to further purify the sample from proteins, salts, 
phospholipids and other agents that cause ion suppression (explained in the next section), 
and to make sure the sample is compatible with LC-MS/MS analysis. 
 
There are several options available for purifying the sample, with the most commonly 
used three being: a) protein precipitation (PPT), b) liquid-liquid extraction (LLE) or c) 
solid phase extraction (SPE), which can be performed online or off-line. There are 
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automated systems available that perform these procedures and can be coupled to the LC-
MS/MS system to speed up the process and provide higher through-put [7]. PPT is the 
quick and easy option, but it is very non-selective and can require frequent maintenance 
of the instrument because of the introduction of unnecessary matrix components onto the 
MS. On the other hand, LLE and SPE are technically laborious but offer much cleaner 
extracts. Additional sample pre-treatment that can be performed to optimize separation 
from interferences or enhance the sensitivity of the analyte is derivatization. Once the 
sample preparation procedure has been finalized, it is essential to re-optimize both the 
MS and the LC methods and to make sure all stages of the LC-MS/MS method are 
compatible and synchronized. 
II.2. LC-MS/MS Method Validation 
II.2.1. Ion Suppression 
Ion suppression, also known as matrix effect, is thought to occur mainly as a result of 
nonvolatile solutes originating from the sample matrix interfering with the ionization of 
the analyte of interest by altering the efficiency of droplet formation or droplet 
evaporation, which in turn affects the amount of charged ions in the gas phase reaching 
the detector and compromises the sensitivity of the LC-MS/MS assay [8]. Examples of 
materials shown to cause ion suppression include salts, ion-pairing agents, endogenous 
compounds, drugs, metabolites, and proteins. Importantly, the degree of ion suppression 
can be dependent on the concentration of analyte studied, which underscores the 
importance of using concentrations of analyte that reflect those that will be encountered 
under physiological conditions [9]. The post-column infusion method presented here 
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(Figure II.3) provides a qualitative assessment of matrix effects by identifying 
chromatographic regions where ion suppression/enhancement is most likely to occur. 
This test cannot be performed for endogenous compounds without an isotope-labeled 
internal standard. Concentration of analyte should be in the physiological range at the 
mass spectrometer source. 
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Figure II.3: Post-column infusion set-up used to evaluate the effect of absolute ion 
suppression. The dashed line represents the signal of the analyte in solvent matrix, while 
the full line is obtained when a blank matrix is injected. The arrow is pointing to a region 
of ion suppression. Reproduced from [10]. 
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II.2.2. Mixing Study 
The objectives of this experiment are three-fold: i) verify that the internal standard used 
accounts for ion suppression by behaving similar to the analyte in the matrix tested, ii) 
choose a matrix to be used as calibration matrix and diluting high samples, and iii) 
demonstrate reliability by testing various lots. The mixing study can be used for both 
exogenous and endogenous compounds. It is evaluated by extracting and injecting patient 
samples (n=6), a candidate matrix solution, and 1:1 mixtures of patient samples with the 
candidate matrix solution. The criteria for a passing test is the response ratio (analyte/IS) 
of each 1:1 mixture was within 20% of the theoretical response calculated from an 
average of the measured values of the patient and candidate matrix solution. 
II.2.3. Method Interference (based on CLSI EP7-A2 guideline) 
An interferent is a substance either exogenous or endogenous that affects or interferes 
with the measurement of a target analyte. An interferent study should be performed to 
assess the effects of common interferents on the target analytes. To determine if a 
substance would interfere under “worst case” conditions, the comprehensive interference 
screen should be conducted at the highest concentrations that a laboratory would expect 
to observe among patient specimens submitted for analysis.  Since both positive and 
negative effects might occur from different mechanisms (e.g. hemoglobin has catalyst 
activity as well as strong absorbance in the visible spectrum) each substance should be 
tested at two different analyte concentrations to avoid the possibility that competing 
effects might cancel at the concentrations tested.  Alternatively, appropriate low and high 
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controls or proficiency samples may be run containing multiple possible interfering 
substances.  A minimum of triplicate sample preparations/extractions using two different 
analyte concentrations is necessary. 
II.2.4. Analytical Measurement Range (AMR)/Calibration 
The analytical measurement range (AMR) also known as linearity determines the values 
over which an accurate and repeatable value will be identified. Coefficient of variation 
(%CV)/relative standard deviation (%RSD) and recovery are used to determine the range. 
Functional sensitivity is determined with this assay. The AMR is determined in the 
linearity study with accuracy within 100 ± 20%, a total coefficient of variation (CV) 
within 20%, and a signal to noise greater than 10.The possible calibration range is 
determined by the AMR. A calibration/standard curve defines the relationship between a 
given analyte concentration and instrument response. A calibration curve should include 
five to eight-points covering the analytical measurement range and a zero calibration 
(matrix sample processed with internal standard), is necessary. After AMR is completed a 
full calibration should be performed with all assays.  
II.2.5. Method Carryover 
Carryover is defined as the amount of analyte not removed from an analytical system 
from a previous run. It is advisable to obtain a sample that is the highest possible 
concentration that could be received in a laboratory sample. All samples greater than the 
approved carryover must have the subsequent patient sample(s) repeated. Carryover is 
evaluated by 3 independent experiments each consisting of running two extractions in the 
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sequence of low1-high-low2, where low2 is a re-injection of low1. A passing test means 
low1 is within 20% of low2, and that low2 is within 3 standard deviations of the low1 
value. The standard deviation is determined using low1 values. High samples that are 
above assay linearity are diluted within the linear range and the values are back 
calculated. The dilution is used to determine actual concentration that action must be 
taken if value is higher.  
II.2.6. Assay Precision (based on CLSI EP10-A3 guideline) 
Precision determines how repeatable a target analyte can be measured. Both total and 
within-run (intra-assay) precision must be evaluated using three different analyte 
concentrations. Precision is evaluated using a modified protocol based on the Clinical 
Laboratory and Standards Institute (CLSI) EP10-A3 guideline (Wayne, PA, USA) and 
includes running the sequence mid-hi-low-mid-mid-low-low-hi-hi-mid twice a day for 5 
days using patient derived samples to determine both intra-assay and total CVs. The 
sequence used in the primary method was specifically designed to allow the nearly 
uncorrelated estimation of the effects of non-linearity, sample carryover, proportional and 
constant bias, and linear drift. This is also the time for assaying quality control (QC) 
materials. QC materials are made separately from precision samples but may be at the 
same analyte levels. Minimum of two QC levels need to be used. At least one QC sample 
is placed at the beginning and end of a batch and must be alternated.  
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II.2.7. Assay Comparisons (Comparative Accuracy) 
Assay comparisons are a way of determining the accuracy of a method. This is also 
known as analytical method comparison (AMC).There are multiple ways that the AMC 
can be achieved. Comparisons that can be performed for this test are listed below in order 
of preference: 
1. Reference Material: Assess accuracy by measuring certified reference materials if 
possible (e.g. National Institute of Standards and Technology). 
2. Comparison with a Reference Method: Accuracy can also be estimated by 
measuring patient samples (~40 initially) by both the new method and a reference 
method.   
3. Commonly Used Method: If neither a reference material nor comparison with a 
reference method is available, a comparison may be done using a commonly used 
method.   
II.3. Conclusion 
LC-MS/MS has become widely utilized in the clinical laboratory because it offers an 
unparalleled level of sensitivity and specificity for small molecule analysis. The process 
of developing and validating LC-MS/MS methods is rigorous and requires highly 
specialized training. However, the process can be standardized and procedures written 
down, greatly facilitating it and the lab can be confident that they are producing accurate, 
precise and reliable methods for clinical use.  
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CHAPTER III  
 
 
 
EVALUATION OF L-ARGININE, SYMMETRIC DIMETHYLARGININE, AND 
ASYMMETRIC DIMETHYLARGININE AS BIOMARKERS FOR 
CARDIOVASCULAR AND KIDNEY DISEASE 
 
III.1. Introduction 
Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine 
(SDMA) are formed by hydrolysis of the proteins with post-translational methylation of 
arginine residues catalyzed by protein arginine methyltransferases [1]. ADMA is a potent 
endogenous inhibitor of nitric oxide synthase and an established biomarker for 
endothelial function [2,3]. SDMA, a structural isomer of ADMA, is an emerging 
biomarker for renal function that has been shown to outperform creatinine-based 
equations for determining estimated glomerular filtration rate, commonly referred to as 
eGFR [4,5]. ADMA and SDMA have been independently associated with increased 
cardiovascular and all-cause mortality, while ADMA has been established as a new 
independent cardiovascular risk factor [6,7]. ADMA is also elevated in people with 
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hypercholesterolemia, atherosclerosis, hypertension, chronic heart failure, diabetes 
mellitus and chronic renal failure [8].  
 
In the past decade, increased interest in conducting clinical research investigating 
associations between ADMA, SDMA and various disease states has led to a surge in 
analytical method development. Initially, high-performance liquid chromatography 
(HPLC) with fluorescence detection, capillary electrophoresis or ion exchange 
chromatography with absorbance detection were applied to the measurement of these 
analytes in human blood or urine [9]. However, the need for derivatization and long 
chromatographic separation has promoted the need for faster and simpler methods. 
Hence, an ELISA assay was developed for the measurement of ADMA, however, it 
seemed to suffer from matrix effects producing concentration-dependent positive bias 
compared to a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
[10]. LC-MS/MS is considered the “gold standard” for the measurement of these analytes 
[9,11]. However, some of these methods do not measure SDMA [12,13], some require 
lengthy derivatization procedures [14-17], and the others have relatively long 
chromatography time [18-24]. 
 
In this study, our primary aim was to develop and validate a simple and fast LC-MS/MS 
assay for the measurement of ARG, SDMA and ADMA suitable for the demands of a 
high volume clinical research laboratory. Our secondary aim was to fully characterize 
these analytes including establishing reference intervals, investigating the impact of pre-
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analytical variables, and investigating correlations with biomarkers of kidney function 
(creatinine, MDRD eGFR, and CKD-EPI eGFR) and cardiovascular disease (hsCRP). 
III.2. Materials and Methods 
III.2.1. Chemicals, Reagents and Solutions 
Methanol and acetonitrile (Burdick and Jackson High Purity Solvent) were from 
VWR (West Chester, PA, USA). Type 1 water was from a Millipore Synergy System 
(Billerica, MA, USA). ARG (as L-arginine), SDMA [as NG, NG’-dimethyl-L-arginine di 
(p-hydroxyazobenzene-p’-sulfonate) salt], ADMA (as NG, NG-dimethylarginine 
dihydrochloride), formic acid (for mass spectrometry, ~98%) and ammonium formate 
(LC-MS grade) were purchased from Sigma (St. Louis, MO). The internal standards (IS), 
ARG-IS [as L-arginine:HCl (U-13C6, 97-99%)] and ADMA-IS [as ADMA:HCl:H2O 
(2,3,3,4,4,5,5-d7, 98%)] were purchased from Cambridge Isotope Laboratories, Inc. 
(Andover, MA). Saline (as 0.9% sodium chloride irrigation, USP) was obtained from 
Baxter Healthcare Corporation (Deerfield, IL). A silica column, Polaris Si-A 5 µm, 100 × 
4.6 mm, was purchased from Varian, Inc. (Palo Alto, CA). 
 
Two different stocks were prepared in water for ARG (56.54 mM and 28.24 mM) and 
ADMA (3.63 mM and 4.00 mM), and in 0.1N HCl for SDMA (266 µM and 314 µM). 
One stock was used for preparation of standard solutions, while the other was used for 
preparing quality controls and validation materials. The calibration standards were 
prepared in saline by serial dilution at 428.6, 214.3, 107.1, 53.6 and 10.7 µM for ARG, at 
4.43, 2.22, 1.11, 0.55 and 0.11 µM for SDMA and at 4.43, 2.22, 1.11 and 0.55 µM for 
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ADMA. IS stocks were prepared in water at 2.32 mM for ARG-IS and 1.90 µM for 
ADMA-IS. An IS mix was prepared in water at 55.5 µM of ARG-IS and 0.76 µM of 
ADMA-IS. All solutions were stored at -70°C in Corning (Corning, NY) cryogenic vials 
until use. 
III.2.2. Sample Preparation 
Sample preparation consisted of adding 50 µL of the IS mix to 50 µL of plasma, 
calibrator, or quality control samples in polypropylene microcentrifuge tubes and 
vortexed for  5 seconds followed by protein precipitation with 300 µL of 1% ammonium 
acetate in methanol. The mixture was vortexed for 5 s then centrifuged for 10 min at 
13,000 × g. The supernatant (100 µL) was mixed with 300 µL of 1% formic acid in 
acetonitrile in an LC-MS certified sample vial (Waters; Milford, MA, USA) with 25 µL 
injected for analysis. 
III.2.3. LC-MS/MS Method 
This method was developed on a Thermo Fisher TSQ Quantum Access with a TLX-4 
HPLC system. Instrument software for this study consisted of Tune Master 1.5, Aria 
1.6.1, and Xcalibur 2.0.7. The quadruplex HPLC system consisted of two robotic 
sampling arms and a refrigerated sampling compartment for six 96-well plates followed 
by four parallel and independent inline degassers, binary HPLC pumps, and quaternary 
HPLC pumps. Mobile phase A was 25 mM ammonium formate in water with 1% formic 
acid and mobile phase B was methanol. Samples were injected on the Polaris Si-A 
analytical column at a flow rate of 0.8 mL/min and a mobile phase composition of 15:85 
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A:B for 3 min. Then, the column was washed with 90:10 A:B at 0.7 mL/min for 0.5 min 
and re-equilibrated for 1.5 min with 15:85 A:B at 0.8 mL/min before the next injection. 
The total run time between injections for one channel is 5.0 min. The mass spectrometer 
was set to positive electrospray ionization. The spray voltage was set at 5000 V and the 
capillary temperature at 280°C. The sheath gas was 50 U, the ion sweep gas was 35.0 U, 
and the aux gas was 10 U. Multiple reaction monitoring was set to monitor the (M+1) 
transitions listed in Figure III.1. The collision energy was 23, 27, 12, 17, and 28 for ARG, 
ARG-IS, SDMA, ADMA, and ADMA-IS, respectively. The tube lens offset was set at 81 
for all analytes. 
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Figure III.1: Representative chromatograms of an extracted patient plasma sample 
showing multiple reaction monitoring transitions, retention times (RT), absolute areas 
(AA), and signal to noise ratios (SN) 
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III.2.4. Method Validation 
Absolute ion suppression was evaluated by post-column infusion of a saline solution 
containing 5.52 µM of ARG-IS and 4.76 µM of ADMA-IS, while extracted patient 
samples (3 males and 3 females) without IS were injected into the system. Relative ion 
suppression was studied to test whether the IS accounted for ion suppression in the matrix 
for the analytes. It is evaluated by extracting and injecting a candidate matrix solution 
(saline spiked with ARG at 142.9 µM, and SDMA and ADMA at 1.47 µM), 6 patient 
samples (3 males and 3 females), and 1:1 mixtures of patient samples with the candidate 
matrix solution. The criteria for a passing test is the response ratio (analyte/IS) of each 
1:1 mixture was within 20% of the theoretical response calculated from an average of the 
measured values of the patient and candidate matrix solution. Interference from lipemic, 
hemolytic, uremic and icteric plasma samples was investigated at two different analyte 
concentrations (low and high) by mixing each sample 1:1 with saline spiked with ARG at 
42.8 µM, and SDMA and ADMA at 0.44 µM for low and ARG at 85.6 µM, and SDMA 
and ADMA at 0.88 µM for  high. It was determined that there was no significant 
interference if the response ratio of each 1:1 mixture was within 20% of the theoretical 
response calculated from the average of interference containing sample and the spiked 
saline. Linearity was examined in triplicate by serially diluting with saline an EDTA 
plasma pool spiked with high concentration of each analyte. The endogenous 
concentrations of these analytes in the patient pool were determined by analyzing 
unspiked aliquots and were accounted for in the calculation. The analytical measurable 
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range was determined for each analyte in the linearity study with accuracy within 100 ± 
20%, a total coefficient of variation (CV) within 20%, and a signal to noise greater than 
10. Carryover was evaluated by 3 independent experiments each consisted of running two 
extractions in the sequence of low1-high-low2, where low2 is a re-injection of low1. A 
passing test meant low1 is within 20% of low2, and that low2 is within 3 standard 
deviations of the low1 value. The standard deviation was determined using low1 values. 
High samples that were above assay linearity were diluted within the linear range and the 
values were back calculated. Precision was evaluated using a modified protocol based on 
the Clinical Laboratory and Standards Institute (CLSI) EP10-A3 guideline (Wayne, PA, 
USA) and included running the sequence mid-hi-low-mid-mid-low-low-hi-hi-mid twice a 
day for 5 days using patient derived samples to determine both intra-assay and total CVs. 
Statistics were calculated using Excel (Microsoft, Redmond, WA, USA) or EP Evaluator 
Release 9 (Data Innovations, South Burlington, VT, USA). 
III.2.5. EDTA Plasma Tube and Serum Separator Tube (SST) Comparisons 
Left-over EDTA plasma and SST serum samples that were drawn from the same 
patients (n = 20) via a single venipuncture were extracted within 24 h after blood draw 
along with calibrators and QCs and analyzed in a single batch. Significant difference was 
defined as over 20% between the two tube types. 
III.2.6. Temperature Stability 
Left-over patient EDTA whole blood (n = 10) was centrifuged at 2000 g for 10 
min. With the plasma still sitting on the packed cells, one aliquot from each tube was 
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frozen at -70°C for baseline measurement, while the original five tubes were stored at 
either 2-8°C or room temperature (RT). One aliquot from each tube was moved to the -
70°C freezer after 2 h, 6 h, 96 h, and 192 h at the specific storage conditions, 
respectively. Significant change was defined as a concentration change over the baseline 
by >20%. 
III.2.7. Freeze/Thaw Stability 
Left-over patient EDTA whole blood (n = 6) was centrifuged at 2000 g for 10 
min. Three plasma aliquots (1 mL) spiked with 20 µL of combined sub-stock (7.14 mM 
ARG and 73.8 µM of SDMA and ADMA) along with 3 unspiked plasma samples were 
frozen at -70°C. Tubes were thawed and an aliquot per tube (150 µL) was transferred to a 
separate vial and refrozen at -70°C along with the original specimen tubes. This process 
was repeated with the original tubes for 5 freeze/thaw cycles. All samples were then 
thawed and analyzed in one batch. 
III.2.8. Sample Collection for Reference Range Determination 
Collection of blood samples for reference range determination was approved by 
the Cleveland Clinic Institutional Review Board. In brief, EDTA whole blood samples (n 
= 51) were collected from healthy adults (12 males, 39 females), aged 19-64 y (38.8 ± 
12.6), after over 8 h fasting. Exclusion criteria were: body mass index (BMI) below 15 or 
above 30, had a cold, flu, virus or an infection in the past two weeks, diagnosed with 
diabetes, malabsorption syndrome or Crohn’s disease, gastric or intestinal surgery, or 
frequent diarrhea, had received chemotherapy in the past year, on immunosuppressant 
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drugs, or pregnancy. Blood samples were centrifuged within 2 hours of collection at 2000 
g for 10 min and the plasma was aliquoted into cryogenic vials and stored at -70°C until 
analysis. All the reference range samples were analyzed with QCs and calibrators in a 
single batch. 
III.2.9. Sample Collection for Correlation with Biomarkers of Kidney Function 
Collection of blood samples for correlation with biomarkers of kidney function 
was approved by the Cleveland Clinic Institutional Review Board. Left-over EDTA 
whole blood samples (n=132) were selected to cover a wide range of creatinine 
concentrations that ranged from 0.30 to 12.54 ng/dL (2.83 ± 2.45 ng/dL). Samples 
collected were not stored more than 72 hours refrigerated before being centrifuged at 
2000 g for 10 min, aliquoted and frozen at -70°C until analysis. All samples were thawed 
and analyzed with QCs and calibrators on the same day in separate batches. A linear 
regression model was applied to each pair of variables and the slope coefficient was 
calculated. Creatinine and the two eGFR calculations (MDRD and CKD-EPI) had 
skewed distributions, and log-transformations were performed before correlation. A P-
value <0.05 indicated significance. 
III.2.10. Sample Collection for Correlation with High Sensitivity-C Reactive Protein 
Collection of blood samples for correlation with high sensitivity C Reactive 
Protein (hsCRP) was approved by the Cleveland Clinic Institutional Review Board. Left-
over EDTA whole blood samples (n=102) were selected to cover three categories of 
hsCRP, low relative risk for cardiovascular disease (CVD) (hsCRP < 1.0 mg/L, n=27), 
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average relative risk for CVD (hsCRP: 1.0 – 3.0 mg/dL, n=50), and high relative risk for 
CVD (hsCRP: 3.0 – 10.0 mg/dL, n=25). Samples collected were not stored for more than 
72 hours refrigerated before being centrifuged at 2000 g for 10 min, aliquoted and frozen 
at -70°C until analysis. All samples were thawed and analyzed with QCs and calibrators 
on the same day in separate batches. Means and standard deviations were summarized by 
each hsCRP category. ANOVA was used to examine the association between each 
variable and hsCRP category. The Pearson correlation was also calculated by treating 
hsCRP as a continuous variable.  
III.3. Results and Discussion 
III.3.1. Method Development 
Methanol with 1% ammonium acetate was selected as our extraction solvent because 
visually it gave the largest pellet after centrifugation compared to methanol, acetonitrile, 
or acetonitrile with 1% formic acid. In addition, it showed the least absolute ion 
suppression among the 4 tested solvents. Furthermore, addition of acetonitrile with 1 % 
formic acid to the methanol with 1% ammonium acetate extract (3/1) significantly 
improved the peak shape of the analytes. The use of a silica column with high organic 
mobile phase was selected because it offered the shortest chromatography time among 
methods published for underivatized ARG and methylated derivatives [24]. At the time 
of this work, isotope replaced SDMA was not commercially available. Therefore 
ADMA-IS was used as the internal standard for SDMA and extensive evaluation of 
matrix effect and accuracy was performed to confirm the validity of this approach. In 
comparison with published methods, some do not measure SDMA [12,13], some require 
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lengthy derivatization procedures [14-17], and the others have longer chromatography 
time [18-24]. 
III.3.2. Chromatography 
Representative chromatograms for the analytes and internal standards from an 
extracted patient sample are shown in Figure III.1. Total analytical cycle time, including 
column re-equilibration, was 5 min using a single LC channel. Chromatographic 
resolution of SDMA and ADMA was not necessary because each was monitored using a 
unique mass transition. However, monitoring a second transition was not possible 
because there were no other unique fragments with significant intensity. Therefore 
extensive validation including interference study was performed to ensure a robust 
performance. The retention time (mean ± standard deviation) for ARG and ARG-IS was 
2.20 ± 0.01 min, for SDMA was 2.50 ± 0.02 min, and for ADMA and ADMA-IS was 
2.67 ± 0.03 min (n = 121) in plasma samples. 
III.3.3. Assay Validation 
Significant absolute ion suppression was observed only for ARG, however, all 
analytes passed the relative ion suppression test, with mean difference between the 
measured concentrations in the mixtures and the theoretical concentrations (n = 6) of 
1.36%, 2.32%, and 0.78% for ARG, SDMA and ADMA, respectively. This indicates that 
ARG-IS sufficiently compensated the ion suppression for ARG, and that ADMA-IS was 
an acceptable internal standard for quantifying both SDMA and ADMA. No interference 
was observed from lipemic, hemolytic, uremic or icteric plasma samples for all analytes. 
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Linearity was determined to be 5.7-489.7 µM for ARG, 0.06-5.15 µM for SDMA, and 
0.34-5.65 µM for ADMA with the accuracy ranging from 99 to 120% (Table III.1). The 
high recovery values seen for the lower end of ADMA may be due to the background 
signals. However the current confirmed sensitivity is sufficient to measure ADMA at the 
human plasma levels. No significant carryover was observed up to a tested concentration 
of 776 µM for ARG, 9.06 µM for SDMA and 9.08 µM for ADMA. The intra-assay and 
total CVs were all within 7.7% for all levels tested (Table III.2).  
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Table III.1: Precision and recovery data from the linearity study 
 
Analyte Mean, 
µM 
Analytical 
recovery %CV 
ARG 5.7 105% 4.2% 
 
28.7 107% 1.8% 
 
54.8 102% 1.7% 
 
108.2 101% 3.9% 
 
213.5 99% 1.4% 
 
335.9 105% 7.2% 
 
489.7 101% 8.8% 
SDMA 0.06 117% 1.6% 
 
0.33 118% 2.5% 
 
0.65 118% 1.8% 
 
1.26 112% 1.6% 
 
2.4 107% 2.9% 
 
3.51 104% 10.2% 
 
5.15 101% 2.9% 
ADMA 0.08 155% 12.2% 
 
0.34 120% 4.8% 
 
0.65 114% 4.0% 
 
1.22 106% 2.9% 
 
2.52 111% 2.4% 
 
3.72 109% 5.2% 
  
5.65 110% 2.2% 
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Table III.2: Precision data based on CLSI EP10-A3 protocol 
 
                    
 
ARG SDMA ADMA 
  Low Mid High Low Mid High Low Mid High 
n 30 30 30 30 30 30 30 30 30 
Mean, µM 24.3 85.9 146 0.4 0.96 1.51 0.41 1.14 1.89 
Total %CV 3.1 2.7 3.9 4.2 5.9 7 7.7 3.7 5.2 
Intra-assay %CV 1.8 2.6 3.9 3.9 3.8 4.7 4.5 3.2 5.3 
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III.3.4. Preanalytical Variables 
Although EDTA plasma is the most commonly used sample type for the 
measurement of these analytes, SSTs are more commonly used in the clinical lab. Using 
left-over paired SST and EDTA specimens from 20 patients, we observed that SST serum 
showed a large positive bias for ARG (Figure III.2) while matched closely with EDTA 
plasma for SDMA, which was consistent with what has been reported in the literature 
[25,15]. However, the comparison result for ADMA was inconsistent with other reports 
which showed an insignificant difference between SST and EDTA plasma [15]. Our data 
showed only 75% (n = 15/20) of the samples matched between the two tube types for 
ADMA measurements. The discrepancy in results may be explained by the smaller 
number of samples used in the other study (n=4). As a result, we concluded that only 
EDTA plasma was the acceptable specimen type for all the analytes in this assay. 
 
Di Gangi et al. found that ARG, SDMA, and ADMA are all stable for up to 120 h in 
plasma at RT , 4°C, and -20°C [15]. However, there has been no report regarding the 
stability of these analytes in EDTA plasma in contact with packed blood cells after 
centrifugation. Our data (Table III.3) showed that ARG, SDMA, and ADMA kept on the 
blood cells after centrifugation were stable for 6 h at RT while at 2-8°C ARG was stable 
for 6 h, SDMA for 192 h, and ADMA for 96 h. All the analytes were found stable up to 5 
freeze/thaw cycles in this study, in agreement with previous reports showing that all the 
analytes where stable up to at least 4 freeze/thaw cycles [26]. 
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Figure III.2: Bland-Altman (A, B, C) and percent Bland-Altman (D, E, F) plots 
comparing SST with EDTA plasma for ARG (A and D), SDMA (B and E) and ADMA 
(C and F) 
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Table III.3: Stability of ARG, SDMA and ADMA in EDTA plasma 
 
ARG SDMA ADMA  
Conc. 
(µM) % Recovery of  t = 0h 
Conc. 
(µM) % Recovery of  t = 0h 
Conc. 
(µM) % Recovery of  t = 0h 
Time Sample 0h* 2h 6h 96h 192h 0h* 2h 6h 96h 192h 0h* 2h 6h 96h 192h 
1 32.3 97.2 94.0 88.5 84.6 1.0 107.6 102.8 129.4 115.4 0.6 87.9 94.8 134.5 117.0 
2 23.9 97.1 98.8 81.1 54.4 1.2 100.2 98.9 100.2 109.3 0.9 104.1 99.7 117.5 126.0 
3 47.5 101.7 95.3 68.1 52.6 0.6 102.3 100.8 108.3 119.1 0.6 98.6 100.2 130.8 143.3 
4 39.3 101.3 98.3 107.4 116.2 1.1 101.0 96.6 110.7 125.7 0.6 115.9 109.8 163.9 202.7 
5 31.0 97.4 94.3 67.8 60.6 0.4 100.6 100.5 109.3 130.5 0.4 106.2 102.0 151.4 183.6 
RT 
mean 34.8 98.9 96.1 82.6 73.7 0.8 102.3 99.9 111.6 120.0 0.6 102.5 101.3 139.6 154.5 
6 20.9 98.4 97.8 80.3 63.7 0.9 100.6 95.6 94.7 105.8 0.8 95.2 95.8 98.3 107.7 
7 20.6 99.4 96.7 84.2 51.5 0.7 102.7 100.8 102.9 109.3 0.8 89.0 99.1 102.5 132.7 
8 40.1 103.4 98.3 75.2 55.1 0.4 102.6 97.1 103.9 103.1 0.5 93.4 94.6 106.3 127.1 
9 33.3 96.4 92.8 79.0 55.7 0.7 104.0 103.3 104.8 107.0 0.7 101.9 103.3 111.5 128.0 
10 25.5 101.3 96.9 76.9 62.3 0.8 96.5 93.5 97.6 98.4 0.6 94.2 91.6 102.0 124.9 
2-
8°C 
mean 28.1 99.8 96.5 79.1 57.7 0.7 101.3 98.1 100.8 104.7 0.7 94.7 96.9 104.1 124.1 
*Denotes time of freezing first baseline aliquot and NOT time of draw. 
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III.3.5. Reference Intervals 
Data analysis revealed a near Gaussian distribution of the reference population (n 
= 51, 12 males and 39 females, age 19-64) for ADMA and SDMA while Box-Cox data 
transformation was required for ARG to have a Gaussian distribution (Figure 3). Using a 
parametric method the reference intervals for SDMA and ADMA were determined to be 
0.32 (0.29-0.36, 90% CI) to 0.65 (0.62-0.69, 90% CI) µM and 0.36 (0.33-0.39, 90% CI) 
to 0.67 (0.64-0.71, 90% CI) µM, respectively. Using a transformed parametric method 
the reference interval for ARG was found to be 53.1 (48.5-58.1, 90% CI) to 129.7 (118.5-
142.0, 90% CI) µM.  
 84 
 
Figure III.3: Histograms showing reference population distribution for ARG (Top), 
SDMA (middle) and ADMA (bottom) 
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The reference intervals calculated in this study were in agreement with the 
existing literature (Table III.4). The reference range for ARG in adults is well established 
(21-138 µM) [27], while reference intervals for ADMA and SDMA are not well defined 
though it is generally agreed that average values are 0.4 µM for ADMA and 0.5 µM for 
SDMA [11]. Recent studies using large populations revealed a range of 0.47-0.85 µM for 
ADMA in 980 healthy older adults (60-72 y), a range of 0.36-1.17 µM using 500 non-
smoking healthy adults, and a range of 0.22-0.69 µM in 150 adults (18-65 y) of Bulgarian 
nationality [28-30]. However, an ELISA assay was used to measure ADMA in these 
studies, which may have positive bias at higher concentrations of ADMA [10]. This 
might explain why reference range intervals for ADMA from these studies are generally 
higher than the one established here. Teerlink et al. measured ADMA and SDMA in 2311 
older adults (50-75) by an HPLC method and the reference intervals, which more closely 
resembled our own, were 0.39-0.63 µM and 0.38-0.73 µM, respectively [31]. However, 
this study was exclusively conducted in older adults and ADMA is known to increase 
with age from 0.43 µM at 20-30 y to 0.54 µM at 70-80 y [32]. In addition, the reference 
intervals for ARG, SDMA and ADMA from another study conducted using 238 blood 
donors (112 F and 126 M) aged 19-69 y, also resembled those presented here and were 
determined to be 42-130 µM for ARG, 0.31-0.55 µM for SDMA, and 0.40-0.77 µM for 
ADMA using an HPLC method with fluorescence detection [33]. Similar data was 
reported in other studies that determined reference intervals for ARG, SDMA and 
ADMA using HPLC coupled to fluorescence detection [34,35]. Schwedhelm et al. 
reported 0.311 and 0.732 µM (2.5th and 97.5th percentile) as reference limits for ADMA 
in 1126 non-smoking individuals measured by an LC-MS/MS method [36]. Though the 
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number of subjects included in our study was small (n = 51) they covered a wide age 
range (19-64) with well defined criteria using a thoroughly validated LC-MS/MS method, 
the “gold standard” for analysis. 
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Table III.4: Summary of large scale studies investigating reference ranges for SDMA and 
ADMA 
Population n Age 
group 
(y) 
Method of 
analysis 
SDMA 
(µM) 
ADMA 
(µM) 
Limitations Reference 
Healthy San 
Francisco Bay 
residents 
980 60-72 ELISAa NDb 0.47-0.85 Old 
population 
and ELISA 
use 
[28] 
Healthy 
Caucasians 
500 19-75 ELISA ND 0.36-1.17 Caucasians 
only and 
ELISA use 
[29] 
Healthy Bulgarians 150 18-65 ELISA ND 0.22-0.69 ELISA use [30] 
Cohort study in 
general population 
(Hoorn Study) 
2311 50-75 HPLCc 0.38-0.73 0.39-0.63 Old 
population 
and general 
population 
[31] 
Caucasian blood 
donors 
238 19-69 HPLC + 
fluorescence 
detection 
0.31-0.55 0.40-0.77 Caucasians 
only 
[33] 
Healthy Caucasian 
males 
292 20-75 HPLC + 
fluorescence 
detection 
0.25-0.81e 
0.27-0.88f 
0.30-0.84g 
0.33-0.88h 
0.43-0.69e 
0.45-0.73f 
0.46-0.78g 
0.54-0.79h 
Caucasian 
males only 
[34] 
Fasting Caucasian 
blood donors 
225 18-65 HPLC + 
fluorescence 
detection 
0.29-0.58 0.36-0.63 Caucasians 
only 
[35] 
White, middle-aged 
community 
(Framingham 
Offspring Study) 
1126 56(9)i LC-MS/MSd ND 0.311-
0.732 
White only 
and middle-
age 
population 
[36] 
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III.3.6. Correlations with Biomarkers of Kidney Function 
Data shown for creatinine and eGFR was adjusted for age, gender and race (Table III.5). 
As shown in Table III.5, the variables ARG, SDMA, ARG/SDMA, ARG/ADMA and 
SDMA/ADMA were significantly associated with creatinine and the two eGFR formulae 
(p<0.05), while ADMA was not. However, the strongest correlation with both creatinine 
and eGFR were SDMA, ARG/SDMA and SDMA/ADMA (p<0.001). This data strongly 
suggests that SDMA and its ratios with ARG and ADMA may be useful as endogenous 
biomarkers for kidney function. Further research is needed to compare the performance 
of these endogenous analytes versus creatinine when using actual measurement of GFR. 
III.3.7. Correlations with hsCRP 
Summary and associations of each variable (ARG, SDMA, ADMA, ARG/SDMA, 
ARG/ADMA, and SDMA/ADMA) with hsCRP category are summarized in Table III.6. 
As shown in Table III.6, it appears that ARG, ADMA, and the ratios of ARG/SDMA and 
ARG/ADMA have significant association with hsCRP categories. ARG, ARG/SDMA 
and ARG/ADMA have negative correlation with hsCRP, while ADMA has a positive 
correlation with hsCRP. On the other hand, SDMA and SDMA/ADMA are not 
significantly associated with hsCRP. This data suggests that measurement of ARG, 
ADMA, ARG/ADMA and ARG/SDMA may also be useful as a predictor of CVD 
events. However, further research is needed to establish the utility and proper use of this 
analyte for this purpose. 
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Table III.5: Summary and association (adjusted for age, gender and race) of each variable 
with GFR and mortality information 
 eGFR variable Pearson correlation Estimate P for 
association 
ARG Creatinine -0.04 (-0.21, 0.13) -0.008 (-0.017, 0.002) 0.109 
 eGFR MDRD 0.21 (0.04, 0.37) 0.275 (0.085, 0.464) 0.005 
 eGFR CKD epi 0.25 (0.08, 0.40) 0.224 (0.096, 0.352) 0.001 
 Log Creatinine -0.14 (-0.30, 0.03) -0.004 (-0.007, -0.001) 0.006 
 Log eGFR MDRD 0.18 (0.01, 0.34) 0.005 (0.002, 0.009) 0.005 
 Log eGFR CKD epi 0.17 (0.00, 0.34) 0.005 (0.001, 0.008) 0.007 
SDMA Creatinine 0.50 (0.36, 0.62) 1.03 (0.722, 1.337) <0.001 
 eGFR MDRD -0.54 (-0.65, -0.40) -22.827 (-29.165, -16.489) <0.001 
 eGFR CKD epi -0.65 (-0.74, -0.53) -18.869 (-22.787, -14.951) <0.001 
 Log Creatinine 0.64 (0.53, 0.73) 0.441 (0.35, 0.531) <0.001 
 Log eGFR MDRD -0.66 (-0.74, -0.55) -0.511 (-0.616, -0.406) <0.001 
 Log eGFR CKD epi -0.66 (-0.75, -0.55) -0.496 (-0.597, -0.396) <0.001 
ADMA Creatinine -0.04 (-0.21, 0.13) -0.238 (-1.536, 1.06) 0.72 
 eGFR MDRD -0.09 (-0.26, 0.08) -19.751 (-46.842, 7.34) 0.156 
 eGFR CKD epi -0.10 (-0.27, 0.07) -14.896 (-33.396, 3.604) 0.117 
 Log Creatinine 0.03 (-0.14, 0.20) 0.171 (-0.262, 0.603) 0.44 
 Log eGFR MDRD -0.05 (-0.22, 0.12) -0.179 (-0.681, 0.322) 0.485 
 Log eGFR CKD epi -0.04 (-0.21, 0.13) -0.16 (-0.644, 0.324) 0.518 
ARG/SDMA Creatinine -0.45 (-0.57, -0.30) -0.012 (-0.015, -0.008) <0.001 
 eGFR MDRD 0.70 (0.60, 0.78) 0.348 (0.284, 0.413) <0.001 
 eGFR CKD epi 0.78 (0.70, 0.84) 0.268 (0.229, 0.307) <0.001 
 Log Creatinine -0.66 (-0.75, -0.55) -0.006 (-0.007, -0.005) <0.001 
 Log eGFR MDRD 0.68 (0.58, 0.77) 0.006 (0.005, 0.008) <0.001 
 Log eGFR CKD epi 0.66 (0.56, 0.75) 0.006 (0.005, 0.007) <0.001 
ARG/ADMA Creatinine -0.003 (-0.17, 0.17) -0.003 (-0.008, 0.003) 0.338 
 eGFR MDRD 0.22 (0.05, 0.38) 0.171 (0.061, 0.281) 0.003 
 eGFR CKD epi 0.27 (0.10, 0.42) 0.142 (0.068, 0.216) <0.001 
 Log Creatinine -0.14 (-0.30, 0.03) -0.002 (-0.004, -0.001) 0.006 
 Log eGFR MDRD 0.19 (0.02, 0.35) 0.003 (0.001, 0.005) 0.006 
 Log eGFR CKD epi 0.19 (0.01, 0.35) 0.003 (0.001, 0.005) 0.008 
SDMA/ADMA Creatinine 0.57 (0.44, 0.68) 0.888 (0.671, 1.106) <0.001 
 eGFR MDRD -0.52 (-0.64, -0.39) -16.427 (-21.259, -11.594) <0.001 
 eGFR CKD epi -0.63 (-0.72, -0.51) -13.654 (-16.667, -10.64) <0.001 
 Log Creatinine 0.67 (0.56, 0.75) 0.336 (0.268, 0.403) <0.001 
 Log eGFR MDRD -0.67 (-0.75, -0.56) -0.392 (-0.469, -0.314) <0.001 
 Log eGFR CKD epi -0.67 (-0.75, -0.56) -0.381 (-0.455, -0.307) <0.001 
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Table III.6: Summary and association of each variable (ARG, SDMA, ADMA, 
ARG/SDMA, ARG/ADMA, and SDMA/ADMA) with hsCRP category. 
 All 
(n=102) 
Low 
(n=27) 
Middle 
(n=50) 
High 
(n=25) 
P for 
association 
with hsCRP 
category 
Correlation with 
continuous hsCRP 
(95% CI) 
ARG, ng/mL 48.36 
(19.70) 
54.44 
(23.49) 
49.06 
(17.54) 
40.38 
(17.26) 
0.033 -0.244 (-0.418, -0.052) 
SDMA, ng/mL 0.75 
(0.53) 
0.63 
(0.09) 
0.75 
(0.55) 
0.86 
(0.73) 
0.298 0.243 (0.051, 0.418) 
ADMA, ng/mL 0.56 
(0.09) 
0.52 
(0.05) 
0.56 
(0.08) 
0.59 
(0.12) 
0.014 0.339 (0.154, 0.500) 
ARG/SDMA 75.23 
(36.05) 
89.40 
(42.14) 
75.58 
(31.52) 
59.22 
(32.00) 
0.009 -0.322 (-0.486, -0.136) 
ARG/ADMA 88.46 
(37.15) 
106.45 
(45.38) 
87.73 
(30.42) 
70.47 
(31.39) 
0.002 -0.337 (-0.499, -0.153) 
SDMA/ADMA 1.31 
(0.71) 
1.22 
(0.18) 
1.30 
(0.75) 
1.44 
(0.97) 
0.533 0.202 (0.008, 0.382) 
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III.4. Conclusion 
In conclusion, we have developed an LC-MS/MS assay for measuring plasma ARG, 
SDMA, and ADMA that is simple and fast. This method has been fully characterized for 
clinical research with reference ranges established. Preliminary clinical associations 
suggest that SDMA and its ratios may be used as endogenous markers for kidney 
function, while ARG, ADMA, ARG/ADMA and ARG/SDMA may be useful for 
prediction of cardiovascular events. 
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CHAPTER IV  
 
 
 
DEVELOPMENT AND VALIDATION OF A SIMPLE AND FAST LIQUID 
CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD FOR 
THE QUANTITATION OF NON-RADIOACTIVE IOTHALAMATE IN SERUM 
AND URINE FOR THE DETERMINATION OF GLOMERULAR FILTRATION 
RATE 
 
IV.1. Background 
Assessment of kidney function for the evaluation and management of kidney disease is of 
daily practical use. Glomerular filtration rate (GFR) is a measure of the number of 
functional nephrons in the kidney and it can either be directly measured by monitoring 
the urinary excretion of a marker, or estimated (eGFR) using developed equations that 
include several markers as well as patient demographics [1]. The ideal marker, which 
could be exogenous or endogenous, is freely filtered at the glomerulus, not secreted nor 
reabsorbed [2]. Serum creatinine is commonly used and various mathematical equations 
to estimate GFR derived from serum creatinine are available. However, in several clinical 
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situations either serum creatinine alone or estimated GFR by the MDRD, Cockcroft-
Gault and CKD-EPI equations are not sufficient due to poor precision and accuracy [3]. 
In those instances, as well as in situations where a direct measurement is needed, the gold 
standard approach of GFR measurement is needed. GFR measurement is clinically useful 
to assess the amount of functional renal tissue or mass. The GFR value gives three types 
of information: (1) the absolute filtration rate at that moment, (2) the relative filtration 
rate in comparison with similar individuals in a group, and (3) the percentage filtration 
rate change in an individual, when measured over time.   
 
Historically, GFR was first measured by the renal clearance of an exogenous filtration 
molecule, inulin (first gold standard) [4]. This methodology proved accurate and precise 
when strict research quality procedures, including patient catheterization for urine 
collections, were followed. Such rigorous procedures were difficult to use in clinical 
situations, therefore the renal clearance of endogenous creatinine soon gained widespread 
favor in clinical medicine [5]. Although practical, GFR estimation through the 
measurement of creatinine has very well known limitations rendering it unreliable in 
patients were accurate GFR determination is required [6]. It is actively secreted and 
reabsorbed by renal tubules and eliminated extrarenally in severe CKD [7]. As a result, 
GFR methodology evolved both with regard to GFR marker molecules and 
instrumentation to measure them. Gamma emitter labeled GFR molecules gained 
popularity in the 1960’s; gamma counter analysis proved to be highly sensitive, accurate 
and precise. Today, 125iodine, 51chromium and 99technetium tracers are in use in larger 
medical centers where accurate GFR measurements are used to support transplant, cancer 
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chemotherapy, geriatric/pediatric, and other patients for whom GFR estimates can be 
inadequate [8,9]. The Renal Function Laboratory at the Cleveland Clinic uses 
radiolabeled iothalamate as a tracer (125iodine). 
 
Patient dosimetry for gamma tracer GFR measurements is on the order of a chest x-ray; 
this is a factor of a hundred less than CAT scans and less than many routine nuclear 
medicine scans. The regulatory requirements associated with labeled tracers have limited 
their widespread use, however, and GFR procedures employing non-radioactive (“cold”) 
GFR molecules have become more attractive as the analytical instrumentation has 
become more sensitive. Improvements in HPLC, capillary electrophoresis and mass spec 
instrumental procedures now make it possible to analyze cold, exogenous GFR markers 
in the clinical chemistry lab, not nuclear medicine [10-13]. These new analytical methods 
are much more complex compared to the pipet-and-count gamma procedures, but they do 
eliminate the tracer-related regulatory concerns, i.e. dosimetry, radiation safety training 
and documentation, radioactive waste disposal, etc. However, these suffer from long run 
times and UV based methods are susceptible to interferences. There is currently only two 
published LC-MS/MS based method which measures unlabeled iothalamate in plasma 
and urine [14,15], however the performance of these methods were not compared against 
the gold standard radioactive measurement, they involved lengthy sample preparation and 
chromatography, and no qualifier transition was monitored for greater selectivity. In this 
study, our goal was to develop and validate a simple, fast and highly selective LC-
MS/MS method, and compare its performance to radioactive measurement of 
iothalamate. 
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IV.2. Materials and Methods 
IV.2.1. Chemicals, Reagents and Solutions 
Methanol (Burdick and Jackson High Purity Solvent) was from VWR (West 
Chester, PA, USA). Type 1 water was from a Millipore Synergy System (Billerica, MA, 
USA). Ammonium acetate (98.7%) and sodium hydroxide (NaOH) (98.6%) were 
purchased from Fisher Scientific (Fairlawn, NJ). Formic acid (for mass spectrometry, 
~98%) was purchased from Sigma (St. Louis, MO). Iothalamic acid (IA) was purchased 
as powder (98-102%) from U.S. Pharmacopeia (Rockville, MD). The internal standard 
(IS), sodium iothalamate labeled 13C, 13C, d3 was purchased from Chemtos (Austin, TX). 
An ultra biphenyl column, Ultra Biphenyl 3 µm, 50 × 2.1 mm, was purchased from 
Restek (Bellefonte, PA). 
 
Two different stocks were prepared in methanol:water:10M NaOH (69:29:2) for IA (4.22 
mg/mL and 4.88 mg/mL). One stock was used for preparation of standard solutions, 
while the other was used for preparing quality controls and validation materials. The 
calibration standards were prepared in water by serial dilution at 60, 30, 15, 7.5, 3.25 and 
1.87 µg/mL for IA. IS stock was prepared in methanol:water:10M NaOH (69:29:2) at 
3.50 mg/mL. An IS precipitation solution was prepared in 1% ammonium acetate in 
methanol at 1.75 µg/mL. All solutions were stored at -70°C in Corning (Corning, NY) 
cryogenic vials until use. 
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IV.2.2. Sample Preparation 
Sample preparation consisted of adding 150 µL of the precipitating solution to 25 µL of 
serum, urine, calibrator, or quality control samples in polypropylene microcentrifuge 
tubes and vortexed for 5 seconds followed by protein precipitation with 300 µL of 1% 
ammonium acetate in methanol. The mixture was vortexed for 5 s then centrifuged for 3 
min at 13,000 × g. The supernatant (10 µL) was mixed with 1 mL of distilled water in 
LC-MS certified sample vial (Waters; Milford, MA, USA) with 2 µL injected for 
analysis. 
IV.2.3. LC-MS/MS Method 
This method was developed on an Applied Biosystems QTRAP 5500 system with a 
Shimadzu LC-30AD system. Instrument software for this study consisted of Analyst 1.5. 
Mobile phase A was water with 0.1% formic acid and mobile phase B was methanol with 
0.1% formic acid. Samples were injected on the heated (T = 35°C) Ultra Biphenyl 
analytical column at a flow rate of 0.5 mL/min and a mobile phase composition of 99:1 
A:B for 0.2 min. Then, the mobile phase composition was switched to 1:99 A:B for 0.3 
min for washing, then back to 1:99 A:B for 1.5 min for re-equilibration before the next 
injection. The total run time is 2.1 min. The mass spectrometer was set to positive 
electrospray ionization. The spray voltage was set at 5500 V and the capillary 
temperature at 700°C. The ion source gas 1 was 50 U, the curtain gas was 40.0 U, and the 
ion source gas 2 was 50 U. Multiple reaction monitoring was set to monitor the (M+1) 
transitions listed in Table IV.1. A quantifier and a qualifier ion were monitored for IA 
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while only a single ion was monitored for the IS. The declustering, entrance and collision 
cell exit potentials were 125.0, 5.0, and 30.0, respectively. 
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Table IV.1: Multiple reaction monitoring parameters. 
Q1 Mass (Da) Q3 Mass (Da) Time 
(msec) 
ID CE (volts) 
614.700 486.800 50.0 IA-Qualifier Ion 24.000 
614.700 360.900 50.0 IA-Quantifier Ion 33.000 
619.700 365.900 50.0 IS 35.000 
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Figure IV.1:Chromatograms showing 10 ug/mL of iothalamate (A) and iothalamate-IS 
(B) in serum, and 20 ug/mL of iothalamate (C) and iothalamate-IS (D) in urine. 
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IV.2.4. Method Validation 
Absolute ion suppression was evaluated by post-column infusion of a water solution 
containing 42.2 µg/mL of IA, while extracted patient urine and serum samples (3 males 
and 3 females each) were injected into the system. Relative ion suppression was studied 
to test whether the IS accounted for ion suppression in the matrix for the analytes. It is 
evaluated by extracting and injecting a candidate matrix solution (water spiked with IA at 
60 µg/mL), 6 patient urine and serum samples (3 males and 3 females), and 1:1 mixtures 
of patient samples with the candidate matrix solution. The criteria for a passing test is the 
response ratio (analyte/IS) of each 1:1 mixture was within 20% of the theoretical 
response calculated from an average of the measured values of the patient and candidate 
matrix solution. Interference from lipemic, hemolytic, and icteric plasma samples was 
investigated at two different analyte concentrations (low and high) by mixing each 
sample 1:1 with water spiked with IA at 15 µg/mL and 60 µg/mL. It was determined that 
there was no significant interference if the response ratio of each 1:1 mixture was within 
20% of the theoretical response calculated from the average of interference containing 
sample and the spiked water. Linearity was examined in triplicate by serially diluting 
serum or urine with spiked blank serum or urine, respectively. The endogenous 
concentrations of IA in the patient pools (serum and urine) was zero because the 
compound is exogenous. The analytical measurable range was determined in the linearity 
study with accuracy within 100 ± 20%, a total coefficient of variation (CV) within 20%, 
and a signal to noise greater than 10. Carryover was evaluated by 3 independent 
experiments each consisted of running two extractions in the sequence of low1-high-low2, 
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where low2 is a re-injection of low1. A passing test meant low1 is within 20% of low2, and 
that low2 is within 3 standard deviations of the low1 value. The standard deviation was 
determined using low1 values. High samples that were above assay linearity were diluted 
within the linear range and the values were back calculated. Precision was evaluated 
using a modified protocol based on the Clinical Laboratory and Standards Institute 
(CLSI) EP10-A3 guideline (Wayne, PA, USA) and included running the sequence mid-
hi-low-mid-mid-low-low-hi-hi-mid twice a day for 5 days using patient urine and serum 
samples to determine both intra-assay and total CVs. Statistics were calculated using 
Excel (Microsoft, Redmond, WA, USA) or EP Evaluator Release 9 (Data Innovations, 
South Burlington, VT, USA). 
IV.2.5. Sample Collection for Radioactive versus Non-radioactive Iothalamate 
Comparison 
Patients (n=22) were consented from the entire body of patients arriving for physician-
ordered GFR testing. Patients were recruited to represent the entire spectrum of GFR 
from health through renal failure, based upon their pre-test estimated GFRs, serum 
creatinine values, and other data. GFR was measured as the renal clearance of the 
exogenous GFR marker molecules, 125I – sodium iothalamate (Glofil, Isotex 
Diagnostics, Friendswood, TX) – this is the standard of care – and iothalamate 
meglumine injection USP 60% (Malinkrodt Inc., St. Louis, MO) – this is the tracer that 
we are interested in implementing clinically for patient care in the future.  The markers 
were given to the patient as two subcutaneous doses, delivered into opposite arms. The 
GFR testing procedure was identical to the procedure currently used for GFR testing in 
the Cleveland Clinic Renal Laboratory. Urine samples were collected by voluntary 
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voiding and blood samples were drawn at the beginning and end of each urine collection 
period, i.e. bracketing blood samples. Analysis of marker concentration in all serum and 
urine samples was done by gamma counting (GAMC) of the 125I-iothalamate marker for 
the clinically ordered GFR, and by LC-MS/MS of the non-labeled iothalamate for the 
study GFR. Details of the sample collection protocol are described below. 
 
IV.2.5.1. Specimen type/tube; minimum volumes 
a. Serum and urine samples are collected as described in detail in the PROCEDURES 
section under PRE-ANALYTICAL instructions. 
b. The volume pipetted from each (serum or urine) sample for GAMC analysis is 0.5 mL 
(500 µL).  The minimum volume of whole blood or urine sample required for gamma 
analysis is 2 mL; Renal Lab personnel may obtain and process smaller samples under 
exceptional circumstances. 
c. The volume pipetted from each (serum or urine) sample for LC-MS/MS analysis is 50 
µL. The minimum volume of whole blood or urine required for LC-MS/MS analysis is 2 
mL; Renal Lab personnel may obtain and process smaller samples under exceptional 
circumstances. 
d. Blood samples should be drawn only in Vacutainer SST yellow-top (serum separator) 
tubes.  Urine collections are collected in clean containers with no additive. 
IV.2.5.2. 1. Sample Acquisition and Handling 
GFR test blood and urine sample acquisition from patients (primary samples) 
within the Cleveland Clinic will follow institutional guidelines regarding sample 
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collection. Specimen identification and safety related exposure and radiation guidelines 
are available in detail in Renal Lab MOPS policies: Specimen Labeling Policy and 
Procedure and Maintaining Specimen Identity and Integrity, and Renal Lab Safety 
Manual Sections: Exposure Control Plan and Radiation Safety Manual, Laboratory Use 
of Radioactive Material (section 8).  
IV.2.5.3. Contraindications 
       a. The labeled/unlabeled iothalamate GFR by renal clearance test(s) should not be 
performed if the patient has a true allergy to iodine. If an iodine allergy is suspected the 
patient’s doctor or the staff nephrologist should be consulted. 
       b. The test(s) should not be performed if the patient is pregnant. 
       c. The test cannot be performed if the patient has had a recent nuclear medicine 
procedure involving the administration of an interfering gamma-emitting isotope other 
than technetium. 
       d. The test cannot be performed if the patient cannot collect reliable, complete, 
voluntary voided urine. 
       e. The test cannot be performed if the patient cannot tolerate the hydration necessary 
to obtain acceptable urine flow rates. 
IV.2.5.4. 125iodine-Sodium Iothalamate (Glofil) Dose Preparation 
The Director of the Renal Lab, A5-403, is the approved user, and orders all patient doses 
of 125iodine-sodium iothalamate (IOTH) from the radiopharmacy at Desk Jb3. Renal lab 
personnel, working under the Director’s supervision, obtain the doses. 
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The vial of 125iodine-sodium iothalamate is received and kept in the radiopharmacy (“hot 
lab”) in the Department of Nuclear Medicine at Jb3. 
For each adult patient (age > 18 years), order 15 + 5 microCuries of Glofil drawn up in 
a 0.5 mL insulin syringe, from the radiopharmacy.  
Pick up the dose at the radiopharmacy; have the radiopharmacist sign the DAILY 
ISOTOPE PICKUP LOG, verifying that (at the time of pickup) no product recalls or 
other warnings have been received at Jb3. 
 
The dose is carried to Q7-261, and is stored in the Avanti I isotope refrigerator until use. 
After use, Renal Lab personnel transport the empty dose syringe back to the 
radiopharmacy for disposal. 
IV.2.5.5. Non-labeled Sodium Iothalamate (Conray) Dose Preparation 
        a. The Director of the Renal Lab, Q7-261, will order doses of Conray iothalamate 
meglumine Injection USP 60% (CON) through the department of Nephrology as this 
marker is for research purposes only. Nephrology nursing personnel, working under the 
Directors supervision, will draw up the doses as specified.  
        b. Vials of Conray are received and kept in the medications refrigerator in the Q7 
nursing station, room Q7-268. 
       c. For each adult patient, 0.5 mL (500 µL) of Conray will be drawn up in a 1 mL TB 
syringe. This initial dose will be diluted in the syringe by then drawing up 0.5 mL of 
0.9% saline for injection to give a total volume of 1.0 mL. The unused portions of Conray 
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and saline will be discarded; in no case will the respective vials be used for multiple 
doses.  
IV.2.5.6. Patient Preparation 
          a. Patients are given preparation instructions, by scheduling personnel, in advance 
of the study. The evening before the test, the patient is instructed to drink an additional 
one liter (one quart) of liquid between dinner and bedtime. The morning of the test, the 
patient must drink 500 mL (2 eight oz. glasses) of water or other beverage to initiate a 
diuresis. If the volume or time of the patient’s pre-test hydration vary from this ideal, the 
test may be started if the patient can provide a background urine sample. If pre-test 
hydration is minimal, it is preferable to delay the study at least one-half hour and hydrate 
the patient with at least 500 mL of water. After the dose injections, adjust the hydration 
amount given to the patient as needed. 
b. Patients routinely taking morning doses of a diuretic should be instructed to not 
take the diuretic first thing in the morning, but rather, to bring the diuretic with them to 
the GFR test. They will take the diuretic at the start of the test. 
IV.2.5.7. Test Procedure 
a. All samples will be labeled, at the time of collection, with the patient’s name and date 
of birth identifiers (the patient’s Cleveland Clinic number may also serve as an 
identifier). The official “patient” format label, printed from the patient’s scheduling page 
in Epic, will be used first and foremost. In addition, the test date, sample collection time, 
and sample name/abbreviation will be written, in ink, on the label. 
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b. Examine the patient’s medical chart and talk with them to determine if any 
contraindications to the test exist. If contraindications exist, contact the ordering 
physician, Director of the Renal Lab, or Nephrology Doctor of the Day to explain the 
situation and need to cancel testing. Record and file the contact information as per MOP 
policy. If contraindications do not exist, fill in the initial patient information on the 
Standardized glomerular filtration rate (GFR) Data Form, Version 02/10/2008.  
c. Measure the patient’s height (cm) and weight (kg) and record on the Standardized GFR 
Data Form. As the test continues, fill in test data as indicated on the form. 
d. Have a Nephrology nurse give the patient, by mouth, 5 drops of super-saturated 
potassium iodide solution (SSKI) diluted in about 15 mL of water or other suitable 
beverage. 
e. Immediately before the IOTH/CON dose injections, have the patient void completely 
and record the time at the moment of completion of voiding (Tbkg). This is the 
background urine sample. The sample name code for this sample is Ubkg. All urine 
collection times should be recorded to the nearest minute in the applicable space on the 
Standardized GFR Data Form.  
f. Save an aliquot (5 mL minimum) of Ubkg. The total volume need not be recorded.   
g. Since no interfering isotope test was found as a contraindication in step 4b, no 
background blood sample is needed. If there is any doubt or question about any 
background isotope interference, draw a blood sample in a 5 mL SST tube. Label the 
background blood sample Bbkg. This blood sample and all other blood samples should be 
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drawn as soon as possible after their respective urine collections. The times of the blood 
draws are not recorded.   
h. Have the Nephrology nurse first administer the IOTH dose as a subcutaneous injection 
in the side of the upper arm and note the time (Tinj). Immediately following the IOTH 
injection, the CON dose should be given, in an identical fashion, in the opposite arm. The 
injections should always be above any site where a tourniquet could be applied. 
i. Instruct the patient to drink 10 mL/kg of water or other beverage in the hour following 
the injection, to maintain hydration and insure adequate urine flow as the test progresses. 
Avoid refrigerated or iced beverages. 
j. After a minimum of 60 minutes has passed since the Tinj, and when the patient has a 
voiding urge, instruct the patient to urinate completely and collect the entire specimen. 
Record the time that the urine collection is completed as T0. Label the urine collection 
U0. 
k. Measure the volume, V0, of U0. All urine volumes must be recorded using a graduated 
cylinder; record volume to the nearest milliliter. If the volume, Vo, is>250 mL, record the 
volume and proceed to step l. If the volume is not >250 mL, wait an additional 30 
minutes (minimum) and have the patient void again, record the new void time as T0 
(disregard the earlier T0 time).  Measure this additional urine volume, V02, and add the 
value to V0 to give a new volume for U0. If the total volume is >250 mL, record and go 
to step l. If the volume is still not >250 mL, continue to collect urine until U0 volume is 
sufficient; if this does not occur after 3 hours, the test may have to be discontinued. Call 
ordering physician to discuss discontinuation/re-ordering of test. Document any such 
decision as per MOP policy.  
 113 
 
l. Draw a blood sample and label it B0. 
 m. Once an adequate flow rate has been established and B0 has been drawn, the urine 
collection U0 and any additional urine collected in step k. can be discarded.  
n. Hydrate the patient from this point on at the rate of 200-400 mL/hour. At 
 hydration equilibrium, this rate would provide a urine flow of approximately 3-6 
ml/minute. Hydration volumes may be adjusted at the discretion of the testing personnel; 
patients should be questioned about their comfort and the presence of any symptoms (e.g. 
nausea, dizziness, shortness of breath, etc) regularly throughout the test. Discontinue 
hydration and/or consult with the Nephrology nurse or Doctor of the Day if any 
significant symptoms occur.   
o. After a minimum wait of 30 minutes from the urine collection time, T0, when the 
patient has a voiding urge, have the patient urinate completely and collect the entire 
specimen. Record the time that the collection is completed,T1. Label the urine U1. 
Measure the volume of U1, record the volume, V1, and save the entire specimen. 
p. Calculate the flow rate: V1 / (T1 – T0 ). The flow rate must be at least 1.0 ml/minute 
for collection U1 and all following collections. If the flow rate is sufficient, go to step q. 
If not, wait additional time, as in step k., and collect additional urine to mix with U1 until 
the flow rate is adequate. The technologist may accept lower urine flow rate collections, 
at their discretion, where exceptionally difficult circumstances exist. The urine must be 
physically mixed before any processing. Similarly, record the final T1 time as the 
collection time and V1, the collection volume. 
q. Collect blood sample and label B1. 
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r. If more than one test period is desired, repeat steps o. through q.; for example, for a 
second gfr urine collection, record time T2; measure and record the volume, V2, of urine 
U2, and draw and label blood B2. This step may be repeated for additional collections if 
desired. Number them sequentially. 
IV.2.5.8. Sample Processing and storage 
a. Whole blood specimens should be centrifuged for 10 minutes at 3000 RPM in the 
PowerSpin MX centrifuge. Inspect specimens post-spin to insure silicone gel has sealed 
off cells. After centrifugation, GAMC of samples will proceed in a timely fashion for 
clinical purposes. Serum may be stored in primary tube, at room temperature, for up to 
one week after GAMC. Store GAMC serum samples for longer intervals at 2 – 8°C. LC-
MS/MS analysis of serum samples will occur as batch runs at a later time. Aliquots of 
serum samples will be stored at -70°C until LC-MS/MS analysis.  
b. GAMC and LC-MS/MS urine samples are processed with no further routine 
preliminary preparation. If the urine sample contains suspended debris, cells, etc., spin an 
aliquot in a 15 mL Falcon urine tube (BLUE MAXTM Jr. 15 ml Polypropylene Conical 
Tube, 17 X 120mm, Becton Dickinson Labware) at 2500 RPM for 15 minutes. 
Pipette/store the clear supernatant for analysis. GAMC of samples will proceed in a 
timely fashion for clinical purposes. Urine may be stored in primary containers at 2 – 8°C 
for up to one week after GAMC analysis. LC-MS/MS analysis of urine samples will 
occur as batch runs at a later time. Aliquots of urine samples will be stored at -70°C until 
LC-MS/MS analysis.  
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IV.3. Results and Discussion 
IV.3.1. Method Development 
During the early stages of development, several reverse-phase analytical columns were 
tested including C18 Kinetex (Phenomenex, Torrance, CA) and Hypersil Gold aQ 
(Thermo Scientific, Waltham, MA), but the Ultra Biphenyl column used gave the best 
peak shape. Similarly, various extraction solvents were tested, including acetonitrile, 1% 
formic acid in acetonitrile, methanol and 1% ammonium acetate in methanol at various 
dilution ratios. Acetonitrile was ruled out because IA was sparingly soluble in it and 
therefore a concentrated precipitation IS mixture could not be prepared using acetonitrile. 
Methanol with 1% ammonium acetate provided the cleanest extract and best sensitivity 
among the remaining options and was used to prepare the precipitation mixture. In 
addition, the final water dilution step was optimized at 1:100 (supernatant:water) and 2 
uL injected because the method was very sensitive and the sample needed to be diluted 
much further to provide a wider dynamic range and to prevent detector saturation at high 
concentration of IA. In comparison with the existing method, the 2.1 min run time of this 
method makes it significantly faster. In addition, the same sample preparation is applied 
for both urine and serum here, which makes sample preparation very easy and fast for the 
technician. Furthermore, this method employs ion ratios (quantifier and qualifier ion) and 
is therefore highly selective in comparison with other existing methods. This combination 
of advantages makes this method highly adaptable to a clinical laboratory setting. 
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IV.3.2. Method Validation 
Significant absolute ion suppression was not observed for IA in either urine and serum 
and it passed the relative ion suppression test, with mean difference between the 
measured concentrations in the mixtures and the theoretical concentrations (n = 6 for 
each) of -1.86%, and -0.76% for serum and urine, respectively. No interference was 
observed from lipemic, hemolytic or icteric plasma samples for all analytes. Linearity in 
serum and urine was determined to be 0.44-62.1 µg/mL and 1.73-423 µg/mL with the 
accuracy ranging from 80 to 97% and 100 to 111%, respectively (Table IV.2). No 
significant carryover was observed up to a tested concentration of 407 µg/mL. The intra-
assay and total CVs were all within 7.2% for all levels tested (Table IV.3). 
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Table IV.2: Precision and recovery data from the linearity study 
Iothalamic 
acid 
in 
Mean, 
µg/mL 
Analytical 
recovery %CV 
Serum 0.44 80% 13.3% 
 
1.03 94% 8.4% 
 
2.30 84% 4.3% 
 
4.63 84% 2.2% 
 
9.39 85% 5.6% 
 
26.8 97% 4.7% 
 
37.3 95% 2.1% 
 
53.9 96% 5.5% 
 
62.1 88% 12.1% 
Urine 1.73 111% 5.0% 
 
3.18 102% 3.3% 
 
6.38 102% 4.7% 
 
12.6 101% 1.2% 
 
25.4 101% 2.8% 
 
50.1 100% 5.1% 
 
102 102% 1.0% 
 
213 106% 1.8% 
 
423 106% 4.3% 
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Table IV.3: Precision data based on CLSI EP10-A3 protocol 
              
 Serum Urine 
  Low Mid High Low Mid High 
n 30 30 30 30 30 30 
Mean, µg/mL 3.88 24.7 44.4 9.0 96.7 188 
Total %CV 7.2 6.8 6.9 6.2 3.6 3.9 
Intra-assay 
%CV 6.7 2 2.2 3.0 0.9 0.7 
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IV.3.3. Radioactive versus Non-radioactive Method Comparison 
Comparison of the GFR results obtained from measuring iothalamate using the LC-
MS/MS method versus the radioactive method showed a mean difference of 2.656 
mL/min/1.73m2 and the Deming regression analysis showed a slope of 1.056 (95%CI: 
1.002 to 1.111), intercept of -0.454 (95% CI: -9.827 to 2.920) and standard error of 
estimate of 3.572. Coefficient of correlation (R) was 0.9940. This data suggests that the 
two methods agree closely with a few exceptions, which required us to keep collecting 
patient samples and compare again with a larger number of patients. The scatter plot, 
Bland Altman plot and percent Bland Altman plot are displayed Figure IV.2, IV.3 and 
IV.4, respectively. 
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Figure IV.2: Scatter plot displaying GFR results from Non-radioactive LC-MS/MS 
versus Radioactive gamma counting. 
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Figure IV.3: Bland Altman plot showing the difference in GFR results between the 
radioactive gamma counting method and the non-radioactive LC-MS/MS method (bias) 
versus the average of the two methods. 
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Figure IV.4: Percent Bland Altman plot showing the percent difference in GFR results 
between the radioactive gamma counting method and the non-radioactive LC-MS/MS 
method (bias) versus the average of the two methods. 
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IV.4. Conclusion 
We have developed a simple and fast LC-MS/MS assay for the measurement of sodium 
iothalamate in serum and urine. The ability to perform the same sample preparation for 
urine and serum is very advantageous because it is simpler for the technician performing 
the test and both can be quantified off the same calibration curve. In addition, the rapid 
chromatography employed (2.1 min) allows for high throughput analysis, and the use of 
ion ratios provides enhanced selectivity for this assay. 
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CHAPTER V  
 
 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
V.1. Chapter I 
The results obtained from the pilot study comparing the effectiveness of vitamin D2 
versus vitamin D3 in restoring normal 25OHD levels in pre-dialysis CKD patients were a 
surprise even in such a small patient sample population. The existing literature seemed to 
point to a direction that suggested that vitamin D3 would clearly emerge as the more 
effective form; however this study demonstrates that the difference is not clear cut and 
easy to discern. Larger prospective studies must be performed to completely discern the 
differences between the two analogues, but we would recommend using different dosing 
patterns because this one is clearly ineffective as only 50% (n=8) in both treatment 
groups reached target levels. This work is being prepared for publication. 
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Furthermore, we have collected additional tubes from the patients enrolled in this study 
that will be used to measure associations of certain cardiovascular and kidney 
biomarkers, such as ADMA and SDMA, to treatment with vitamin D in CKD patients.  
V.2. Chapter II 
The method validation protocol presented in this Chapter has been completely developed 
in-house and is a useful resource for the validation of LC-MS/MS assays that will go into 
clinical use. A more detailed version of this protocol, which provides step-by-step 
instructions to validation, is stored in LabQMS at the Cleveland Clinic. The great 
advantage that this protocol provides over existing guidelines is that it gives detailed 
step-by-step procedures for method validation from data acquisition to data analysis. We 
have already used this protocol for most LC-MS/MS methods developed at the Cleveland 
Clinic, and several of these have already been published [1-6]. This protocol will 
certainly continue to be used and further refined as the technology evolves.  We are 
currently submitting the detailed protocol for publication. 
V.3. Chapter III 
The reported method for the measurement of Arginine, SDMA and ADMA is a 
significant enhancement over existing methods in terms of throughput and simplicity of 
the sample preparation procedure. The determined reference range is in concordance with 
what has been reported in the literature using larger patient populations and LC-MS/MS. 
The developed method has already been published [1]. The clinical data obtained shows 
good correlation between SDMA and its ratios with markers of kidney function, and 
ADMA and its ratios with markers of cardiovascular disease. 
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Additional large cohort studies should be performed to demonstrate the clinical utility of 
these tests. SDMA should be evaluated against the gold standard way of determining 
GFR in clinical practice, iothalamate clearance, and compare its performance to 
creatinine and creatinine-based equations. Once comparison with actual GFR is available, 
this data will be prepared for publication. 
V.4. Chapter IV 
The newly developed method for the measurement of non-radiolabeled iothalamate is a 
significant enhancement over existing methods. The simple sample preparation which 
involves only PPT prior to injection is the same for both urine and serum and provides an 
added level of convenience for the technologist performing the test. In addition, the 
sample volume requirement is lower (25 µL), and chromatography time is significantly 
shorter (2.1 min), which greatly enhances the throughput of this method. Furthermore, the 
use of ion ratios (qualifier/quantifier) provides higher degree of selectivity over existing 
methods, and data showing the correlation of this method with the existing gold standard 
radioactive method prove that this method is accurate as well. 
 
Further studies that need to be done include additional collection of patient samples to 
cover the entire spectrum of GFR values (ideally n = 40). Once all 40 patients have been 
measured, the procedure will be published. Furthermore, additional studies must be 
performed on the non-radioactive iothalamate to confirm it is safe to use in adults as well 
as children, such as degradation. 
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Appendix A 
Patient Consent Form 
The Cleveland Clinic Foundation 
Consent to Participate in a Research Study 
Study title:    UPGRADE: A Randomized, Double-Blind Study to Evaluate the 
Effectiveness of Cholecalciferol versus Ergocalciferol following Kidney 
Disease Outcomes Quality Initiative (K/DOQI) Guidelines for Vitamin D 
Therapy in Stages Three and Four Chronic Kidney Disease (CKD) 
Patients. 
 
Principal Investigator:   James Simon, MD 
 
Please carefully review this consent document. The purpose of a consent document is to 
provide you with information to help you decide whether you wish to participate in this 
research study. Your decision is completely voluntary and will not affect your medical 
care if you choose not to participate.  It is important for you to ask questions and 
understand the research risks, benefits and alternatives.   
 
• You are being asked to participate in a research study 
• Your participation is voluntary 
• Carefully consider the risks, benefits and alternatives of the research 
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Your health care provider may be an investigator in this research study, and as 
investigator, is interested in both your welfare and in the conduct of the study.  Before 
entering this study or at any time during this research, you may ask for a second opinion 
about your care from another doctor who is in no way associated with the research study.  
You are not under any obligation to participate in any research project offered by your 
doctor. 
1.  INFORMATION ON THE RESEARCH 
Why Are You Being Asked To Take Part In This Research?  
You are being asked to take part in this study because you have decreased kidney 
function (chronic kidney disease or CKD), low vitamin D levels in your blood and an 
elevated level of a substance called parathyroid hormone (PTH) in your blood.  
Why Is This Study Being Done? 
It is very common to have low levels of vitamin D in your blood. This form of vitamin D 
is also called “inactivated” vitamin D because the body (mainly the kidneys) has to 
activate it before it provides most of its benefits. You get vitamin D from 2 main sources: 
sunlight and food (dairy product, certain fish). Despite drinking dairy products such as 
milk and going out in the sun, many people cannot maintain normal levels of vitamin D. 
Vitamin D deficiency is common in patients with kidney disease. Having low vitamin D 
levels has been associated with increased risk for falls, broken bones, diabetes, cancer, 
high blood pressure, heart disease and certain immune disorders called autoimmune 
disease. In addition, this problem can stimulate the overproduction of a hormone called 
parathyroid hormone, or PTH. This hormone can lead to problems with weakened bones 
or hardening of the arteries. There are treatment guidelines (K/DOQI guidelines) 
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published by the National Kidney Foundation that outline how to replace vitamin D 
levels in patients with kidney disease. However, how often vitamin D levels are fully 
replaced when following these guidelines have not been studied. In addition, there are 
different formulations of vitamin D that can be given. The guidelines recommend a form 
called ergocalciferol (Vitamin D2). Research data suggests that an alternate form, called 
cholecalciferol (Vitamin D3) may be more effective at building up the vitamin D levels in 
your blood. No one has compared these head-to-head to determine which is better in 
patients with kidney disease.  
In addition, studies suggest that replacing vitamin D levels in kidney disease can help 
reduce the PTH levels back to normal ranges in a portion of patients. It is unclear how 
many people have this benefit or what dose is necessary to do this. If replacing vitamin D 
does not normalize PTH levels, your provider may prescribe a more expensive compound 
called an “activated” vitamin D medication. Therefore, it is important to establish 
whether the “inactivated” Vitamin D (D2 and D3) can normalize PTH levels when 
following the published guidelines.  
This study will help determine which vitamin D compound, ergocalciferol or 
cholecalciferol, is more effective at replacing vitamin D in your blood when used 
according to the current published K/DOQI guidelines. It will also determine how well 
the K/DOQI guidelines work to replace low vitamin D levels and lowering the elevated 
PTH levels. The treatment of your low vitamin D levels will follow current standard of 
care, except that there is a 50/50 chance you will be assigned to use cholecalciferol, 
which is not currently part of the published guidelines.  
 135 
The U.S. Food and Drug Administration (FDA) has approved vitamin D2 (ergocalciferol) 
for commercial use for the treatment of low Vitamin D levels. Vitamin D3 is available 
over-the-counter at lower doses and by prescription at higher doses equivalent to those 
approved for D2. It has been previously studied at the higher doses used in this study and 
deemed to be safe and effective. 
The purpose of this study is to examine the effectiveness of vitamin D3 versus vitamin 
D2 in raising vitamin D and suppressing PTH levels of patients with kidney disease not 
on dialysis. 
How Many People Will Take Part In The Study? 
This study will include a total of about 86 subjects enrolled from the Cleveland Clinic 
Nephrology clinics at Main Campus and the Westlake Family Health Center.  
What Is Involved In The Study? 
If you are eligible for this study, you will be randomly assigned (flip of a coin) to one of 
the following treatment groups: 
1. Vitamin D2 treatment group  
2. Vitamin D3 treatment group 
Initial Screening: 
Once you give your consent to participate in the study, any required labwork that is not 
already available from within the last 45 days will be ordered. If this is the case, you will 
be asked to go to the lab and have about 2 teaspoonfuls of blood collected to check these 
missing labs. This may be part of your routine labwork. Since we have already 
determined that you meet the criteria to join the study, we will not wait for these extra 
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results before starting the study medication. If you are a woman of child-bearing 
potential you will also have a blood pregnancy test performed. 
Information on your date of birth, gender and race will be recorded.  In addition, your 
medical record will be reviewed and pertinent medical problems, medications, vital signs 
or exam findings will be recorded for the study. 
We will dispense the study Vitamin D medication (either D2 or D3) to you today. The total 
duration of this study will be 38 weeks – the first 24 weeks are the Treatment Phase, the 
following 12 weeks are the Follow-Up Phase, and the final 2 weeks are for us to contact 
you at the end of the study. 
Treatment Phase: 
The Treatment Phase will last for 24 weeks. You will begin taking the vitamin by mouth 
today.  How often you have to take the vitamin D supplement will depend on how low 
your vitamin D level is. This will be explained to you by the study investigator. You will 
be given stickers to place on your calendar to remind you when to take the medication. 
You will have labwork once every 6 weeks during this period. About 2 teaspoonfuls of 
blood will be drawn at weeks 6, 12, 18, and 24 to measure your PTH, vitamin D, 
calcitriol, and renal function panel. A study investigator or a research nurse will call you 
to remind you to have your blood drawn and to ask if you are experiencing any side 
effects that might be related to the medication. If we were unable to fully replace your 
vitamin D levels at the end of 24 weeks, you will not continue on to the Follow-Up Phase 
of the study.  
Follow-Up Phase: 
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The Follow-Up Phase will last for 12 weeks. The purpose of this phase of the study is to 
see how well a daily multivitamin maintains your vitamin D levels once we have replaced 
them. If you are in either treatment group and your vitamin D level is normal at 24 
weeks, you will stop taking the prescribed 50,000 IU capsules, and start taking daily 
multi-vitamin capsules which contain no more than 400 IU of vitamin D per capsule.  
You will be asked to give blood 2 more times during this phase, at weeks 30 and 36. The 
same tests will be run as during the Treatment phase. The total amount of blood to be 
drawn over the course of the study will be about 14 teaspoonfuls over the course of about 
9 months. 
Before every scheduled lab draw, a study investigator will contact you to ask if you are 
having any medical problems that might be related to the study medications, to make sure 
you are still taking the medications as prescribed and to remind you about your upcoming 
labwork.   
All labwork must be collected at either a Cleveland Clinic Main Campus laboratory or 
one of the Cleveland Clinic Family Health Center laboratories. Please do not go to a 
Cleveland Clinic-affiliated hospital lab or to a non-Cleveland Clinic lab for this study. 
Telephone Contacts: 
You will be contacted via telephone by a study participant 1-2 weeks before your 
scheduled labs are due to be drawn. During this phone interview, you will be asked about 
medication compliance, whether any outside vitamin D or other prohibited medication is 
being used, whether calcium supplementation is being used and any adverse side effects. 
You will be reminded to have your 6-week interval blood tests done. If blood tests are not 
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completed within the allotted time frame, you will be contacted again by telephone to 
remind them again to have their blood drawn. Phone calls will occur according to the 
following time-frame: week 4, 10, 16, 22 (and weeks 28 and 34 if you are included in the 
Follow-Up Phase). 
Exit Interview 
An exit telephone interview will take place between week 24 and 26 for those patients 
censored after the Treatment Phase and between weeks 36 and 38 for those included in 
the Follow-up Phase. Subjects will be asked all of the questions in the above Telephone 
Interview as well as be informed that the study has ended. If you decide to withdraw from 
the study, an exit interview will be performed at the time of withdrawal unless one was 
performed in the last 2 weeks.  
How Long Will You Be In The Study? 
If you complete the study, your time in the study will be approximately 38 weeks. 
2.  RISKS AND DISCOMFORTS  
What Are The Risks Of The Study? 
Vitamin D2 and D3 are generally well tolerated. All side effects are rare enough that 
percentages of patients who experience them are unpublished. Rare or previously 
unknown or unforeseeable side effects, which may be serious, may occur.  You will be 
monitored closely for these side effects, and if your doctor thinks it is necessary, your 
study drug will be stopped.  If you experience any side effects, you should notify your 
doctor or a study investigator immediately. 
Common risks  
Nausea, vomiting and diarrhea 
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In our clinical experience, while still rare, these are the most common side effects. You 
might experience stomach pains after taking the medication. Less often you may 
experience nausea, vomit or have loose stools. 
High Vitamin D levels 
If taken at too high of a dose for too long, Vitamin D levels may become too high. This 
rare event can lead to a problem called hypervitaminosis D, which can lead to high 
calcium levels in your blood, headache, nausea, vomiting, lethargy, confusion, abdominal 
pain, increased urination, increased thirst, muscle weakness, and in severe cases problems 
with your heart rhythm or deposition of calcium into other organs. To avoid this, your 
blood tests will be monitored frequently enough to identify if the Vitamin D or calcium 
levels become concerning. In this case, you will be called and asked to either stop the 
medication or decrease how often you are taking it.  
Drawing blood 
The risks of drawing blood from a vein includes discomfort at the site of the needle stick, 
possible bruising and swelling around the site of the needle stick, rarely an infection, and 
uncommonly feeling faint from the procedure. 
Uncommon risks 
Allergic Reaction 
Allergic reactions to vitamin D compounds are very rare. However, there is always the 
potential for an allergic reaction to a medication. Symptoms of an allergic reaction could 
include a rash, itching, low blood pressure, breathing difficulties or swelling. If you 
develop signs and symptoms of an allergic response, you should contact your physician or 
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a study coordinator immediately to determine whether you should stop taking the study 
medication. If you experience difficulty swallowing or breathing, chest discomfort, the 
feeling that you are going to pass out or any other symptoms you might consider life-
threatening, you should call 911 or go directly to an emergency room. 
If you agree to participate, you or your family members should tell your nurse or doctor 
immediately if you have any unusual health experiences, injuries or side effects while 
you are in this study. 
Unknown risks 
Pregnancy 
The risks of vitamin D supplementation to an unborn child are unknown. Studies in 
animals suggest that if vitamin D levels are too high (Hypervitaminosis D), there may be 
risks to the unborn child. Therefore, if you are capable of giving birth to a child, you and 
your sexual partner should use adequate birth control measures while you are in the 
study.  These measures may include but are not limited to abstinence, oral contraceptives 
(birth control pills), IUD, diaphragm, Norplant, approved hormone injections, condoms, 
or documentation of medical sterilization.  If you are unwilling to do this, we ask that you 
not participate in this study.  
If you do become pregnant while taking part in this study you must notify the study 
investigator immediately. The study medication will be stopped and you will be 
withdrawn from the study. We may request initial pregnancy information and information 
on the pregnancy outcome for both the mother and child. 
Breastfeeding 
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High levels of calcium have been detected in children who are breastfeeding from 
mothers taking large doses of vitamin D. Therefore if you are breastfeeding, you will not 
be able to participate in this study. 
3.  BENEFITS 
Are There Benefits To Taking Part In The Study? 
The study drug and supplement, vitamin D2 and D3, are expected to increase vitamin D 
and lower PTH levels in patients with chronic kidney disease not on dialysis. It has been 
suggested that this may have long-term benefits on your bone health and heart health, 
among others. However, no guarantee of any results or outcome can be made. 
You do not have to take part in this study to be treated for your vitamin D deficiency, 
your kidney disease or any other condition you have.  If you decide to be in this study, it 
is possible that you will receive no direct benefit.   
4.  ALTERNATIVES 
What Other Options Are There? 
If you do not participate in this study, it is likely that your doctor will recommend that 
your low vitamin D levels be treated with ergocalciferol, one of the study drugs, in 
exactly the same manner as is prescribed in the study. They may also prescribe 
cholecalciferol, the other study drug, at lower doses available over-the-counter. 
Alternatively, they may not recommend treatment. Other medical therapies for secondary 
hyperparathyroidism include the administration of phosphate binders, calcium, 
cinacalcet, and/or calcitriol. Phosphate binders can lower your serum phosphorus levels, 
and cinacalcet, calcium and calcitriol can decrease your PTH levels. However, no 
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alternatives other than vitamin D2 or vitamin D3 exist for treatment of low vitamin D 
levels. 
5.  PRIVACY AND CONFIDENTIALITY 
Will Your Information Be Kept Private? 
The medical and research information recorded about you will be used within the 
Cleveland Clinic as part of this research.  The results of your bloodwork done solely for 
this research study may be placed in your medical record. Otherwise, a copy of the 
results will be forwarded to your nephrology provider. Upon completion of the study, you 
may have access to the research information if contained in the medical record. Your 
medical records may also be reviewed and copies made by members of either the 
institutional review board/independent ethics committee responsible for this trial site or a 
regulatory agency. 
Your access to research information about you will be limited while the study is in 
progress.  Preventing this access during the study keeps the knowledge of study results 
from affecting the reliability of the study.  This information will be available should an 
emergency arise that would require your treating physician to know this information to 
treat you best. 
Your research information may be disclosed to the Cleveland Clinic research review staff 
and the U.S. Food and Drug Administration.  The Cleveland Clinic also may use and 
disclose this information for treatment and payment reasons.  The Cleveland Clinic must 
comply with legal requirements that mandate disclosure in unusual situations. Otherwise, 
the information recorded about you as part of this research will be maintained in a 
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confidential manner.  It is possible that information disclosed about you outside the 
Cleveland Clinic could be re-disclosed and no longer protected by federal privacy laws.  
Your research information may be used and disclosed indefinitely, but you may stop 
these uses and disclosures at any time by writing to Dr. James Simon, at The Cleveland 
Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, 216-445-4891.  If you 
do so, any information previously disclosed cannot be withdrawn.  The Cleveland Clinic 
will not use or disclose the information collected in this study for another research 
purpose without your written permission; unless the Cleveland Clinic Institutional 
Review Board gives permission after ensuring that appropriate privacy safeguards are in 
place. The Institutional Review Board is a committee whose job is to protect the safety 
and privacy of research subjects.   
Federal Regulations require that you authorize the release of any health information that 
may reveal your identity. The persons and entities that you are authorizing to use or 
disclose your individually identifiable health information may include the study doctor, 
the study staff, Cleveland Clinic monitors/auditors, and the IRB, the U.S. Food and Drug 
Administration and the Department of Health and Human Services (DHHS). Because of 
the need to release information to these parties absolute confidentiality cannot be 
guaranteed. 
By signing this informed consent form, you are authorizing such access to your medical 
records. 
If you choose not to sign this consent form, you will not be permitted to participate in this 
research study. 
6.  RESEARCH RELATED INJURIES 
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What Happens If An Injury Occurs? 
If physical injury occurs due to your involvement in this research, medical treatment is 
available, but your medical insurance will be billed the cost of treatment.  
The Cleveland Clinic will not voluntarily provide compensation for medical expenses or 
any other compensation for research-related injuries. Further information about research-
related injuries is available by contacting the Institutional Review Board at (216) 444-
2924. 
7.  COSTS 
What Are The Costs?  
The Cleveland Clinic will pay for the study drug and supplement, and extra study specific 
tests that are not routine and only being performed because you are participating in this 
study.  You will not be charged for these specific tests. You will receive the study drug 
and supplement free of charge as long as you participate in this study. The Cleveland 
Clinic will not pay for the costs of procedures, tests, visits and hospitalizations not in 
connection with this study. 
Because many of the lab tests required for this study would normally be performed even 
if you didn’t participate in the study, some of the study lab tests will be billed to your 
insurance company.  
You will receive by mail $10 dollars for each study related blood draw (7) and vouchers 
for free parking if the lab at main campus is used. There is no parking fee to park at the 
CCHS family health centers. 
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It is possible that through the use of your medical data and sample for exploratory 
research, a commercial pharmaceutical product may be developed from your medical 
data and/or samples. If you decide to sign this consent form you are releasing (giving) to 
Cleveland Clinic your blood sample, the by-products of your sample, and any products 
developed from the sample or use of the sample. Cleveland Clinic, other researchers, or 
research companies may patent or sell discoveries that result from this research. Neither 
Cleveland Clinic nor the principal investigator will compensate you if this happens. 
8.  VOLUNTARY PARTICIPATION 
What Are Your Rights As A Participant? 
Taking part in this study is voluntary. You will be told of any new, relevant information 
from the research that may affect your health, welfare, or willingness to stay in this study. 
You may choose not to take part or may leave the study at any time.  Withdrawing from 
the study will not result in any penalty or loss of benefits to which you are entitled.  If 
you decide to withdraw from the study you should discuss with your study doctor your 
decision to ensure a safe withdrawal. 
You will be removed from the study if you receive a kidney transplant, start on dialysis 
or have your parathyroid glands removed. You will also be removed from the study if you 
become pregnant during the study. 
9.  QUESTIONS 
Whom Do You Call With Questions Or Problems? 
If you have any questions about the research, concerns or complaints about the research, 
or develop a research-related problem, you should contact James Simon MD at (216) 
445-4891.  During non-business hours, you should contact the page operator at (216) 
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444-2200; ask for the Nephrology fellow on-call.   If you have questions about your 
rights as a research subject, you should contact the Institutional Review Board at (216) 
444-2924.  You can also contact the Institutional Review Board if you have concerns or 
complaints about the research, if you cannot reach the research team, or wish to talk to 
someone other than the research staff. 
10. SIGNATURE 
Statement of Participant 
I have read and have had verbally explained to me the above information and have had 
all my questions answered to my satisfaction.  I understand that my participation is 
voluntary and that I may stop my participation in the study at any time. Signing this form 
does not waive any of my legal rights.   I understand that a copy of this consent will be 
provided to me. By signing below, I agree to take part in this research study.   
You agree that Cleveland Clinic’s research using your medical data/biologic materials 
may lead to the development of commercial pharmaceutical products. Cleveland Clinic 
and other researchers may use these data and may patent or commercialize discoveries 
or inventions that result from this research. Neither Cleveland Clinic nor other 
participants in this research will compensate you if this happens. 
 
_____________________________ 
Printed name of Participant 
 
_____________________________ ___________  
Participant Signature   Date    
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Statement of Person Conducting Informed Consent Discussion 
 
I have discussed the information contained in this document with the participant and it is 
my opinion that the participant understands the risks, benefits, alternatives and 
procedures involved with this research study. 
 
__________________________________ 
Printed name of person obtaining consent 
 
_______________________________         ___________ 
Signature of person obtaining consent Date  
 
ADDITIONAL BLOOD SAMPLES FOR STORAGE AND FUTURE USE: 
 
In addition to the study labwork, you are being asked to provide 2 additional blood 
samples (2 teaspoonfuls) for each scheduled blood draw during the study for a total of 21 
additional teaspoons over the course of approximately 9 months. If you agree, this blood 
will be saved for future analysis of additional markers that may be associated with CKD. 
These blood samples will be stored indefinitely at Cleveland Clinic Clinical Pathology 
Laboratory 9500 Euclid Ave. /L11, Cleveland, OH. You may request that your blood 
samples be destroyed at any time. The blood samples will be stored without identifying 
information about you (such as your name or Social Security number) but will be marked 
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instead with a coded ID. Your personal information and the ID will be kept in a secure 
computer system that will only be available to study personnel. The use of your blood 
will be under the supervision of the principal investigator Dr. James Simon. No 
information identifying you will be provided to any investigator requesting access to your 
blood samples. These samples will not be used for any genetic studies. The results of any 
testing done on these samples will not be reported to you or your health care provider.  
I AGREE to have additional blood samples  
collected that will be used for future studies   __________              __________ 
          Initial  Date 
I DO NOT agree to have additional blood samples  
collected that will be used for future studies    ___________ _________ 
          Initial  Date 
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Appendix B 
Case Report Form-Screening Sheet 
CCF #: ___________  
STEP 1: INCLUSION CRITERIA 
Is the patient over 18 years of age?      Y/N 
Does the patient have stage 3 or 4 CKD (GFR 15-60cc/min)?  Y/N 
Does the patient have a vitamin D level <30ng/mL?   Y/N 
 
IF YES TO ALL OF THE ABOVE, THE PATIENT MEETS INCLUSION 
CRITERIA, PROCEED TO STEP 2. 
 
STEP 2: EXCLUSION CRITERIA 
Does the patient have:  
History of primary hyperparathyroidism in EPIC?   Y/N    
History of Liver failure?      Y/N 
History of chronic diarrhea or malabsorption syndrome?  Y/N 
Serum calcium >12.0mg/dL?      Y/N 
Treatment with an activated vitamin D formulation (calcitriol,  Y/N 
doxercalciferol or paracalcitol) within the past 6 months? 
Current or expected treatment with phenobarbital, phenytoin,  Y/N 
rifampicin, sucralfate, steroids or digoxin 
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Active malignancy other than squamous or basal cell skin   Y/N 
cancer? 
Is the subject currently pregnant or want to become pregnant in       Y/N                                     
the next year? 
Serum phosphorus level greater than 4.5 or treatment with an  Y/N 
oral phosphate binder within the past 6 months  
Treatment with cinacalcet or other calcimimetic within the past  Y/N 
6 months 
Anticipated dialysis within 6 months after randomization  Y/N 
Inability to swallow tablets      Y/N 
Known sensitivity, intolerance, or other adverse response to the  Y/N 
study drugs which would prevent compliance with study  
medication 
Have an unstable medical condition, defined as having been  Y/N 
hospitalized within 30 days before screening, the expectation of  
recurrent hospital admissions or life expectancy of less than 6  
months in the judgment of the investigator 
Currently enrollment in, or fewer than 30 days have passed since     Y/N 
subject has completed another investigational device or drug  
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study(s); or subject is receiving another investigational agent(s). 
 
IF THE ANSWERS TO ANY OF THE ABOVE IN STEP 2 ARE YES, THEN THE 
PATIENT CANNOT BE ENROLLED IN THE STUDY. 
 
IF ALL THE ANSWERS IN STEP 2 ARE “NO”, THEN THE PATIENT IS 
ELLIGIBLE FOR ENROLLMENT 
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Appendix C 
Phone Interview Form 
Subject identified number: 
Study personnel making the call: 
 
1) Introduction – name, affiliation with the study 
2) Have they been taking their study medicine as scheduled?  Y/N 
3)  Are they taking any other vitamin D supplement?   Y/N 
4) Have they been prescribed paracalcitol, doxercalciferol, calcitriol  Y/N 
or cinacalcet? 
5) Have they become pregnant?      Y/N 
6) Have they been experiencing any side effects from the study  
medication?         Y/N 
If yes, ask if the following: 
 Abdominal pain or cramps?      Y/N 
 Loose stools or diarrhea?      Y/N 
 Constipation?        Y/N 
 Nausea?        Y/N 
 Palpitations?        Y/N 
 Dizziness?        Y/N 
 Muscle cramping or stiffness?     Y/N 
 Twitching?        Y/N 
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Other:_______________________________ 
7) Did they have to stop the study medication as a result?   Y/N 
8) Reminder about the blood work due in the next 1-2 weeks.   
9) Any other questions or concerns?      Y/N 
If yes: _____________________________________ 
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Appendix D 
Adverse Event Reporting Form 
Subject identifier number:_________________________ 
Study Personnel recording the adverse event: ____________________________ 
Adverse event:______________________________ 
Serious or life-threatening?      Y/N 
Was study medication stopped as a result?    Y/N 
Did the patient require: 
 Emergency room visit      Y/N 
 Admission to the hospital     Y/N 
 Invasive procedure as a result of the event   Y/N 
 Did the event lead to death of the subject?   Y/N 
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Appendix E 
Sample Checklists 
UPGRADE Study Sample Checklist 1 
NOT Consented for Research: Week 1 
Last Name: Upgrade   First Name:      
Date & Time Collected   Time Received   Time Frozen   
Centrifuge Type Used    Centrifuge Speed (xg)   
Dr. Sihe Wang:          
Use Memo Account:    
Vial Types (check) 
o Gold 
Requested Tests (check):  
o HCGQT 
o PHOS 
o Other   
For each checked requested test, an aliquot is transferred to a 75x12 mm tube instead of 
cryogenic vials, this form is copied and taken to CPA along with labeled tubes. In Actual 
Volume, write down “CPA” for these samples. Tubes are labeled “Last Name, First Name - 
TubeID” e.g. Upgrade, 001W1Gold1. 
 Tube ID Expected Volume (mL)  Actual Volume (mL) 
o W1Gold1 1.0 For 1,25D        
o W1Gold2 0.5 For requested test       
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o W1Gold3 0.5 For requested test       
 
Comments           
            
            
             
 
UPGRADE Study Sample Checklist 2 
Consented for Research: Week 1 
Last Name: Upgrade   First Name:      
Date & Time Collected  Time Received   Time Frozen   
Centrifuge Type Used   Centrifuge Speed (xg)   
Dr. Sihe Wang:          
Use Memo Account:    
Vial Types (check) 
o Gold (x2) 
o Purple 
Requested Tests (check):  
o HCGQT 
o PHOS 
o Other   
For each checked requested test, an aliquot is transferred to a 75x12 mm tube instead of 
cryogenic vials, this form is copied and taken to CPA along with labeled tubes. In Actual 
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Volume, write down “CPA” for these samples. Tubes are labeled “Last Name, First Name - 
TubeID” e.g. Upgrade, 001W1Gold1. 
 Tube ID Expected Volume (mL)  Actual Volume (mL) 
o W1Gold1 1.0 For 1,25D        
o W1Gold2 0.5 For requested test       
o W1Gold3 0.5 For requested test       
o W1Gold4 1.0 Research        
o W1Gold5 1.0 Research        
o W1Gold6 1.0 Research        
o W1Purple1 0.5 Research        
o W1Purple2 0.5 Research        
o W1Purple3 0.5 Research        
Comments           
            
             
UPGRADE Study Sample Checklist 3 
NOT Consented for Research: Week 6,12, or 24 
Last Name: Upgrade   First Name:      
Week    
Date & Time Collected   Date & Time Retrieved   
Vial Types (check) 
o Tracked down Gold sample 
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Tube ID   Expected Volume (mL)  Actual Volume (mL) 
o W6/12/24Gold1 1.0 For 1,25D       
o W6/12/24Gold2 0.5 For D2/D3       
Comments           
            
            
             
UPGRADE Study Sample Checklist 4 
Consented for Research: Week 6, 12, or 24 
Last Name: Upgrade   First Name:     
Week    
Date & Time Collected   Time Received  Time Frozen   
Date & Time Tracked Gold Tube is Retrieved     
Centrifuge Type Used   Centrifuge Speed (xg)    
Vial Types (check) 
o Tracked down Gold sample 
o Gold 
o Purple 
Gold 1 and 2 are for samples tracked down and aliquoted, while 3, 4 and 5 is for Gold 
tube received for research. 
Tube ID   Expected Volume (mL)  Actual Volume (mL) 
o W6/12/24Gold1 1.0 For 1,25D       
o W6/12/24Gold2 0.5 For D2/D3       
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o W6/12/24Gold3 1.0 Research       
o W6/12/24Gold4 1.0 Research       
o W6/12/24Gold5 1.0 Research       
o W6/12/24Purple1 0.5 Research       
o W6/12/24Purple2 0.5 Research       
o W6/12/24Purple3 0.5 Research       
Comments           
            
            
             
UPGRADE Study Sample Checklist 5 
NOT Consented for Research: Week 18, 30, or 36 
Last Name: Upgrade   First Name:      
Date & Time Collected  Time Received   Time Frozen   
Centrifuge Type Used   Centrifuge Speed (xg)   
Dr. Sihe Wang:          
Use Memo Account:    
Vial Types (check) 
o Gold (x2) 
For Gold1-3, fill in 75x12 mm tubes, label, copy this form and take to CPA along with samples. 
In Actual Volume, write down “CPA” for these samples. Tubes are labeled “Last Name, First 
Name - TubeID” e.g. Upgrade, 001W1Gold1. For Gold 4 and 5, store frozen. 
Requested Tests (check):  
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o PTHI  
o RFP 
o VITD 
Tube ID   Expected Volume (mL)  Actual Volume (mL) 
o W18/30/36Gold1 1.0 For PTHi       
o W18/30/36Gold2 0.5 For RFP       
o W18/30/36Gold 3 0.5 For 25OHD       
o W18/30/36Gold4 1.0 For 1,25D       
o W18/30/36Gold 5 0.5 For D2/D3       
Comments           
            
            
             
UPGRADE Study Sample Checklist 6 
Consented for Research: Week 18/30/36 
Last Name: Upgrade   First Name:      
Date & Time Collected   Time Received   Time Frozen   
Centrifuge Type Used   Centrifuge Speed (xg)   
Dr. Sihe Wang:          
Use Memo Account:    
Vial Types (check) 
o Gold (x3) 
o Purple 
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For Gold1-3, fill in 75x12 mm tubes, label, copy this form and take to CPA along with samples. 
In Actual Volume, write down “CPA” for these samples. Tubes are labeled “Last Name, First 
Name - TubeID” e.g. Upgrade, 001W1Gold1.  For Gold 4-8 and Purple 1-3 store frozen. 
Requested Tests (check):  
o PTHI  
o RFP 
o VITD 
Tube ID   Expected Volume (mL)  Actual Volume (mL) 
o W18/30/36Gold1 1.0 For PTHi       
o W18/30/36Gold2 0.5 For RFP       
o W18/30/36Gold 3 0.5 For 25OHD       
o W18/30/36Gold4 1.0 For 1,25D       
o W18/30/36Gold 5 0.5 For D2/D3       
o W18/30/36Gold6 1.0 Research       
o W18/30/36Gold7 1.0 Research       
o W18/30/36Gold8 1.0 Research       
o W18/30/36Purple1 0.5 Research       
o W18/30/36Purple2 0.5 Research       
o W18/30/36Purple3 0.5 Research       
Comments           
            
             
 
